

Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

*Attorneys for Plaintiffs
Dexcel Pharma Technologies Ltd.
and Dexcel Ltd.*

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

**DEXCEL PHARMA TECHNOLOGIES
LTD. and DEXCEL LTD.,**

Plaintiffs,

v.

**SUN PHARMA GLOBAL FZE, SUN
PHARMA GLOBAL INC., SUN
PHARMACEUTICAL INDUSTRIES, INC.,
and SUN PHARMACEUTICAL
INDUSTRIES, LTD.,**

Defendants.

Civil Action No. _____

**COMPLAINT FOR
PATENT INFRINGEMENT**

(Filed Electronically)

Plaintiffs Dexcel Pharma Technologies Ltd. (“Dexcel Pharma”) and Dexcel Ltd. (collectively, “Plaintiffs”), by their undersigned attorneys, for their Complaint against defendants Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc. and Sun Pharmaceutical Industries, Ltd. (collectively, “Sun”), allege as follows:

Nature of the Action

1. This is an action for patent infringement under the patent laws of the United States, 35 U.S.C. §100, *et seq.*, arising from Sun Pharma Global FZE’s filing of an Abbreviated New Drug Application (“ANDA”) with the United States Food and Drug Administration (“FDA”) seeking approval to commercially market a generic version of Dexcel Pharma’s

Omeprazole Delayed Release Tablets, 20 mg (OTC), prior to the expiration of United States Patent Nos. 9,023,391 (“the ’391 patent”) and 7,255,878 (“the ’878 patent”) (collectively, “the patents-in-suit”), owned by Dexcel Ltd.

The Parties

2. Plaintiff Dexcel Ltd. is a corporation organized and existing under the laws of Israel, having its registered address at 1 Dexcel Street Or-Akiva, Israel 3060000.

3. Plaintiff Dexcel Pharma is a corporation organized and existing under the laws of Israel, having its registered address at 1 Dexcel Street Or-Akiva, Israel 3060000.

4. On information and belief, defendant Sun Pharma Global FZE (“Sun FZE”) is a corporation organized and existing under the laws of the United Arab Emirates, having a principal place of business at Office # 43, Block Y, SAIF-Zone, P.O. Box #122304, Sharjah, United Arab Emirates. On information and belief, Sun FZE is a wholly-owned subsidiary of Sun Pharma Global Inc. On information and belief, Sun FZE is in the business of, among other things, manufacturing and selling generic copies of branded pharmaceutical products throughout the United States, including in this Judicial District.

5. On information and belief, Sun Pharma Global Inc. (“Sun Pharma”) is a corporation organized and existing under the laws of the British Virgin Islands, and maintains a post office box at International Trust Building, P.O. Box No. 659, Road Town, Tortola, British Virgin Islands. On information and belief, Sun Pharma is a wholly-owned subsidiary of Sun Pharmaceutical Industries, Ltd. On information and belief, Sun Pharma is in the business of, among other things, manufacturing and selling generic copies of branded pharmaceutical products throughout the United States, including in this Judicial District.

6. On information and belief, Sun Pharmaceutical Industries, Inc. (“Sun Inc.”) is a corporation organized and existing under the laws of the State of Michigan, having a principal

place of business at 270 Prospect Plains Road, Cranbury, New Jersey 08512. Sun Inc. is a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. On information and belief, Sun Inc. is registered to do business in the State of New Jersey. On further information and belief, Sun Inc. is in the business of, among other things, manufacturing and selling generic copies of branded pharmaceutical products throughout the United States, including in this Judicial District.

7. On information and belief, defendant Sun Pharmaceutical Industries, Ltd. (“Sun Ltd.”) is a corporation organized and existing under the laws of India, having a principal place of business at Acme Plaza, Andheri-Kurla Rd., Andheri (E), Mumbai - 400 059, India. On information and belief, Sun Ltd. is in the business of, among other things, manufacturing and selling generic copies of branded pharmaceutical products throughout the United States, including in this Judicial District.

8. On information and belief, the acts of Sun FZE complained of herein were done with the cooperation, participation, and assistance of Sun Pharma, Sun Inc. and Sun Ltd.

The Patents-in-suit

9. On May 5, 2015, the United States Patent and Trademark Office (“USPTO”) duly and lawfully issued the ’391 patent, entitled “Stable Benzimidazole Formulation.” A copy of the ’391 patent is attached hereto as Exhibit A. Dexcel Ltd. owns the ’391 patent.

10. On August 14, 2007, the USPTO duly and lawfully issued the ’878 patent, entitled “Stable Benzimidazole Formulation.” A copy of the ’878 patent is attached hereto as Exhibit B. Dexcel Ltd. owns the ’878 patent.

The Omeprazole Delayed Release, 20 mg (OTC) Drug Product

11. Dexcel Pharma holds an approved New Drug Application (“NDA”) under Section 505(b) of the Federal Food Drug and Cosmetic Act (“FFDCA”), 21 U.S.C. § 355(b), for Omeprazole Delayed Release Tablets, 20 mg (OTC) (NDA No. 22-032). The claims of the

patents-in-suit cover, *inter alia*, stable formulations of omeprazole and methods of manufacturing omeprazole formulations.

12. Pursuant to 21 U.S.C. § 355(b)(1) and attendant FDA regulations, the '391 patent is listed in the FDA publication, "Approved Drug Products with Therapeutic Equivalence Evaluations" (the "Orange Book"), with respect to Omeprazole Delayed Release Tablets, 20 mg (OTC).

Acts Giving Rise To This Suit

13. On information and belief, Sun FZE has submitted Abbreviated New Drug Application No. 207891 ("Sun's ANDA") to the FDA under Section 505(j) of the FFDCA. Sun's ANDA seeks approval to engage in the commercial manufacture, use, sale, offer for sale or importation of a generic version of Plaintiffs' Omeprazole Delayed Release Tablets, 20 mg (OTC) ("Sun's Proposed Product") prior to the expiration of the patents-in-suit.

14. On information and belief, following FDA approval of Sun's ANDA, Sun FZE, Sun Pharma, Sun Inc. and Sun Ltd. will work in concert with one another to make, use, sell, or offer to sell Sun's Proposed Product throughout the United States, or import such generic products into the United States.

15. In connection with the filing of its ANDA as described in the preceding paragraphs, Sun FZE has provided a written certification to the FDA, as called for by Section 505 of the FFDCA, 21 U.S.C. § 355(j)(2)(A)(vii)(IV) ("Sun's Paragraph IV Certification"), alleging that the claims of the '391 patent are invalid, unenforceable, and/or will not be infringed by the activities described in Sun's ANDA.

16. No earlier than October 2, 2015, Plaintiffs received written notice of Sun's Paragraph IV Certification ("Sun's Notice Letter") pursuant to 21 U.S.C. § 355(j)(2)(B) with respect to the '391 patent. Sun's Notice Letter alleged that the claims of the '391 patent are

invalid, unenforceable, and/or will not be infringed by the activities described in Sun's ANDA. Sun's Notice Letter also informed Plaintiffs that Sun seeks approval to market Sun's Proposed Product before the '391 patent expires.

17. In Sun's Notice Letter, Sun offered to provide access to certain confidential information and materials within Sun's ANDA that would allow Plaintiffs to confirm Sun's infringement of the patents-in-suit. The parties did not reach agreement on the terms of such confidential access. To date, Sun has not provided any portion of its ANDA to Plaintiffs.

Jurisdiction and Venue

18. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

19. The Court has personal jurisdiction over Sun by virtue of, *inter alia*, its systematic and continuous contacts with the State of New Jersey.

20. This Court has personal jurisdiction over Sun FZE, Sun Pharma, Sun Inc. and Sun Ltd. because, *inter alia*, they have committed an act of patent infringement under 35 U.S.C. 271(e)(2), and intend a future course of conduct that includes acts of patent infringement in New Jersey. These acts have led and will lead to foreseeable harm and injury to Plaintiffs. For example, on information and belief, Sun FZE, Sun Pharma, Sun Inc. and Sun Ltd. are actively preparing to make the proposed generic copies of Omeprazole Delayed Release Tablets, 20 mg (OTC), that are the subject of Sun's ANDA, and to use, sell, and offer for sale such generic copies in this State and in this Judicial District.

21. On information and belief, Sun FZE develops, manufactures, and/or distributes generic drugs for sale and use throughout the United States, including in this Judicial District.

22. On information and belief, Sun FZE, with the assistance and/or at the direction of Sun Pharma, Sun Inc. and/or Sun Ltd., develops, manufactures, distributes, markets, offers to

sell, and sells generic drug products for sale and use throughout the United States, including within this Judicial District.

23. On information and belief, Sun FZE, Sun Pharma, Sun Inc. and Sun Ltd. acted in concert to develop Sun's Proposed Product and to seek approval from the FDA to sell Sun's Proposed Product throughout the United States, including within this Judicial District.

24. On information and belief, Sun FZE, Sun Pharma, Sun Inc. and Sun Ltd. participated in the preparation and/or filing of ANDA No. 207891.

25. On information and belief, Sun FZE, alone and/or at the direction of Sun Pharma, Sun Inc. and/or Sun Ltd., has committed, or aided, abetted, actively induced, contributed to, or participated in the commission of an act of patent infringement under 35 U.S.C. § 271(e)(2) that has led and/or will lead to foreseeable harm and injury to Plaintiffs.

26. This Court has personal jurisdiction over Sun FZE because, *inter alia*, Sun FZE, on information and belief: (1) intends to market, sell, or distribute Sun's ANDA products to residents of this State; (2) has committed, or aided, abetted, actively induced, contributed to, or participated in the commission acts of patent infringement that will result in foreseeable harm in New Jersey; (3) maintains a broad distributorship network within this State; and (4) enjoys substantial income from sales of its generic pharmaceutical products in this State.

27. Additionally, on information and belief, Sun FZE has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this Judicial District. *See e.g., Novartis Pharmaceuticals Corp., et al. v. Sun Pharma Global FZE, et al.*, Civil Action No. 12-4393 (SDW)(MCA) (D.N.J.); *The Medicines Co. v. Sun Pharma Global FZE, et al.*, Civil Action No. 11-6819 (PGS)(DEA) (D.N.J).

28. Alternatively, to the extent the above facts do not establish personal jurisdiction over Sun FZE, this Court may exercise jurisdiction over Sun FZE pursuant to Fed. R. Civ. P. 4(k)(2) because: (a) Plaintiffs' claims arise under federal law; (b) Sun FZE would be a foreign defendant not subject to personal jurisdiction in the courts of any State; and (c) Sun FZE has sufficient contacts with the United States as a whole, including, but not limited to, manufacturing and selling generic pharmaceutical products that are distributed throughout the United States, such that this Court's exercise of jurisdiction over Sun FZE satisfies due process.

29. On information and belief, Sun Pharma manufactures and/or distributes generic drugs for sale and use throughout the United States, including in this Judicial District.

30. This Court has personal jurisdiction over Sun Pharma because, *inter alia*, Sun Pharma, on information and belief: (1) has substantial, continuous, and systematic contacts with this State; (2) has committed, or aided, abetted, actively induced, contributed to, or participated in the commission acts of patent infringement that will result in foreseeable harm in New Jersey; (3) intends to market, sell, and/or distribute Sun's infringing ANDA Products to residents of this State; (4) maintains a broad distributorship network within this State; and (5) on information and belief, enjoys substantial income from sales of its generic pharmaceutical products in this State.

31. Additionally, on information and belief, Sun Pharma has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this Judicial District. *See, e.g., Otsuka Pharm. Co. v. Sun Pharm. Indus. Ltd., et al.*, Civil Action No. 14-4307 (JBS)(KMW) (D.N.J. Nov. 19, 2014); *Otsuka Pharm. Co. v. Sun Pharm. Indus. Ltd., et al.*, Civil Action No. 14-6397-JBS-KMW (D.N.J. Dec. 11, 2014); *Aventis Pharms. Inc., et al. v. Sun Pharma Global Inc., et al.*, Civil Action No. 09-325 (GEB)(MCA) (D.N.J. Apr. 3, 2009).

32. Alternatively, to the extent the above facts do not establish personal jurisdiction over Sun Pharma, this Court may exercise jurisdiction over Sun Pharma pursuant to Fed. R. Civ. P. 4(k)(2) because: (a) Plaintiffs' claims arise under federal law; (b) Sun Pharma would be a foreign defendant not subject to personal jurisdiction in the courts of any State; and (c) Sun Pharma has sufficient contacts with the United States as a whole, including, but not limited to, manufacturing and selling generic pharmaceutical products that are distributed throughout the United States, such that this Court's exercise of jurisdiction over Sun Pharma satisfies due process.

33. On information and belief, Sun Inc. develops, manufactures, and/or distributes generic drugs for sale and use throughout the United States, including in this Judicial District.

34. This Court has personal jurisdiction over Sun Inc. because, *inter alia*, Sun Inc., on information and belief: (1) has substantial, continuous, and systematic contacts with this State; (2) is registered to do business in this state under entity ID # 0100970132; (3) is registered as a Wholesale Drug & Medical Device manufacturer and wholesaler by the New Jersey Department of Health and Senior Services; (4) has committed, or aided, abetted, actively induced, contributed to, or participated in the commission acts of patent infringement that will result in foreseeable harm in New Jersey; (5) intends to market, sell, and/or distribute Sun's infringing ANDA products to residents of this State; (6) maintains a broad distributorship network within this State; and (7) on information and belief, enjoys substantial income from sales of its generic pharmaceutical products in this State.

35. Additionally, on information and belief, Sun Inc. has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this Judicial District. *See, e.g., Janssen Pharms. Inc. v Sun*

Pharma Global FZE, et al., Civil Action No. 11-6089 (SRC)(CLW) (D.N.J. Dec. 27, 2011); *Otsuka Pharm. Co. v. Sun Pharm. Indus. Ltd., et al.*, Civil Action No. 14-4307 (JBS)(KMW) (D.N.J. Nov. 19, 2014); *Otsuka Pharm. Co. v. Sun Pharm. Indus. Ltd.*, Civil Action No. 14-6397 (JBS)(KMW) (D.N.J. Dec. 11, 2014).

36. On information and belief, Sun Ltd. develops, manufactures, and/or distributes generic drugs for sale and use throughout the United States, including in this Judicial District.

37. This Court has personal jurisdiction over Sun Ltd. because, *inter alia*, Sun Ltd., on information and belief: (1) intends to market, sell, or distribute Sun's ANDA products to residents of this State; (2) controls Defendants Sun FZE, Sun Global Pharma Inc., and Sun Inc.; (3) operates through its wholly-owned subsidiaries Sun FZE and Sun Inc., at least one of which has a principal place of business in New Jersey, is registered to do business in New Jersey, and is registered as a Wholesale Drug & Medical Device wholesaler and manufacturer by the New Jersey Department of Health and Senior Services; (4) has committed, or aided, abetted, actively induced, contributed to, or participated in the commission acts of patent infringement that will result in foreseeable harm in New Jersey; (5) makes its generic drug products available in this State; (6) maintains a broad distributorship network within this State; and (7) enjoys substantial income from sales of its generic pharmaceutical products in this State.

38. Additionally, on information and belief, Sun Ltd. has previously consented to this Court's jurisdiction and has availed itself of the protections afforded by the Court by asserting counterclaims against plaintiffs in this Judicial District. *See, e.g., Depomed, Inc., et al. v. Sun Pharma Global FZE, et al.*, Civil Action No. 11-3553 (JAP)(TJB) (D.N.J. July 28, 2011); *Otsuka Pharm. Co. v. Sun Pharm. Indus. Ltd.*, Civil Action No. 14-6397 (JBS)(KMW) (D.N.J. Dec. 11, 2014); *Novartis Pharmaceuticals Corp., et al. v. Sun Pharma Global FZE, et al.*, Civil Action

No. 12-4393 (SDW)(MCA) (D.N.J.); *The Medicines Co. v. Sun Pharma Global FZE, et al.*, Civil Action No. 11-6819 (PGS)(DEA) (D.N.J).

39. Alternatively, to the extent the above facts do not establish personal jurisdiction over Sun Ltd., this Court may exercise jurisdiction over Sun Ltd. pursuant to Fed. R. Civ. P. 4(k)(2) because: (a) Plaintiffs' claims arise under federal law; (b) Sun Ltd. would be a foreign defendant not subject to personal jurisdiction in the courts of any State; and (c) Sun Ltd. has sufficient contacts with the United States as a whole, including, but not limited to, manufacturing and selling generic pharmaceutical products that are distributed throughout the United States, such that this Court's exercise of jurisdiction over Sun Ltd. satisfies due process.

40. Venue is proper in this Judicial District pursuant to 28 U.S.C. §§ 1391 and 1400(b).

Count I

Infringement of the '391 Patent

41. Plaintiffs repeat and reallege the allegations of paragraphs 1-40 as though fully set forth herein.

42. Sun FZE's submission of ANDA No. 207891 to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Omeprazole Delayed Release Tablets, 20 mg (OTC), prior to the expiration of the '391 patent, constitutes infringement of one or more of the claims of that patent under 35 U.S.C. § 271(e)(2)(A).

43. There is a justiciable controversy between the parties hereto as to the infringement of the '391 patent.

44. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will infringe the '391 patent under 35 U.S.C. § 271(a) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States.

45. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will induce infringement of the '391 patent under 35 U.S.C. § 271(b) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States. On information and belief, upon FDA approval of Sun's ANDA, Sun will intentionally encourage acts of direct infringement with knowledge of the '391 patent and knowledge that its acts are encouraging infringement.

46. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will contributorily infringe the '391 patent under 35 U.S.C. § 271(c) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States. On information and belief, Sun has had and continues to have knowledge that Sun's Proposed Product is especially adapted for a use that infringes the '391 patent and that there is no substantial non-infringing use for Sun's Proposed Product.

47. Plaintiffs will be substantially and irreparably damaged and harmed if Sun's infringement of the '391 patent is not enjoined.

48. Plaintiffs do not have an adequate remedy at law.

49. This case is an exceptional one, and Plaintiffs are entitled to an award of their reasonable attorneys' fees under 35 U.S.C. § 285.

Count II

Infringement of the '878 Patent

50. Plaintiffs repeat and reallege the allegations of paragraphs 1-49 as though fully set forth herein.

51. Sun FZE, through its submission of Sun's Paragraph IV Certification as part of Sun's ANDA to the FDA, has indicated that it seeks approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Omeprazole Delayed Release Tablets, 20

mg (OTC), prior to the expiration of the '878 patent. Sun's actions with respect to its ANDA show that there is a substantial controversy between the parties of sufficient immediacy and reality to warrant issuance of a declaratory judgment.

52. Sun FZE's submission of ANDA No. 207891 to obtain approval to engage in the commercial manufacture, use, sale, offer for sale, or importation of Omeprazole Delayed Release Tablets, 20 mg (OTC) prior to the expiration of the '878 patent, constitutes infringement of one or more claims of that patent under 35 U.S.C. § 271(e)(2)(A).

53. There is a justiciable controversy between the parties hereto as to the infringement of the '878 patent.

54. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will infringe the '878 patent under 35 U.S.C. § 271(a) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States.

55. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will induce infringement of the '878 patent under 35 U.S.C. § 271(b) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States. On information and belief, upon FDA approval of Sun's ANDA, Sun will intentionally encourage acts of direct infringement with knowledge of the '878 patent and knowledge that its acts are encouraging infringement.

56. Unless enjoined by this Court, upon FDA approval of Sun's ANDA, Sun will contributorily infringe the '878 patent under 35 U.S.C. § 271(c) by making, using, offering to sell, selling, and/or importing Sun's Proposed Product in the United States. On information and belief, Sun has had and continues to have knowledge that Sun's Proposed Product is especially

adapted for a use that infringes the '878 patent and that there is no substantial non-infringing use for Sun's Proposed Product.

57. Plaintiffs will be substantially and irreparably damaged and harmed if Sun's infringement of the '878 patent is not enjoined.

58. Plaintiffs do not have an adequate remedy at law.

59. This case is an exceptional one, and Plaintiffs are entitled to an award of their reasonable attorneys' fees under 35 U.S.C. § 285.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully requests the following relief:

(A) A Judgment be entered that Sun has infringed the patents-in-suit by submitting ANDA No. 207891;

(B) A Judgment be entered that Sun has infringed, and that Sun's making, using, selling, offering to sell, or importing Sun's Proposed Product will infringe one or more claims of the patents-in-suit;

(C) An Order that the effective date of FDA approval of ANDA No. 207891 be a date which is not earlier than the later of the expiration of the patents-in-suit, or any later expiration of exclusivity to which Plaintiffs are or become entitled;

(D) Preliminary and permanent injunctions enjoining Sun and its officers, agents, attorneys and employees, and those acting in privity or concert with them, from making, using, selling, offering to sell, or importing Sun's Proposed Product until after the expiration of the patents-in-suit, or any later expiration of exclusivity to which Plaintiffs are or become entitled;

(E) A permanent injunction, pursuant to 35 U.S.C. § 271(e)(4)(B), restraining and enjoining Sun, its officers, agents, attorneys and employees, and those acting in privity or concert with them, from practicing any methods or compositions as claimed in the patents-in-suit, or

from actively inducing or contributing to the infringement of any claim of the patents-in-suit, until after the expiration of the patents-in-suit, or any later expiration of exclusivity to which Plaintiffs are or become entitled;

(F) A Declaration that the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sun's Proposed Product will directly infringe, induce and/or contribute to infringement of the patents-in-suit;

(G) To the extent that Sun has committed any acts with respect to the methods or compositions claimed in the patents-in-suit, other than those acts expressly exempted by 35 U.S.C. § 271(e)(1), that Plaintiffs be awarded damages for such acts;

(H) If Sun engages in the commercial manufacture, use, sale, offer for sale, and/or importation into the United States of Sun's Proposed Product prior to the expiration of the patents-in-suit, a Judgment awarding damages to Plaintiffs resulting from such infringement, together with interest;

(I) Attorneys' fees in this action as an exceptional case pursuant to 35 U.S.C. § 285;

(J) Costs and expenses in this action; and

(K) Such further and other relief as this Court may deem just and proper.

Dated: November 11, 2015

By: s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

Of Counsel:

F. Dominic Cerrito
Eric C. Stops
Evangeline Shih
Gabriel P. Brier
Catherine T. Mattes
Brian J. Forsatz
QUINN EMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue, 22nd Floor
New York, New York 10010
(212) 849-7000

Robert Green
Caryn Borg-Breen
GREEN, GRIFFITH & BORG-BREEN LLP
NBC Tower, Suite 3100
455 North Cityfront Plaza Drive
Chicago, Illinois 60611
(312) 883-8000

*Attorneys for Plaintiffs
Dexcel Pharma Technologies Ltd.
and Dexcel Ltd.*

CERTIFICATION PURSUANT TO L. CIV. R. 11.2

I hereby certify that the matter captioned *Dexcel Pharma Technologies Ltd., et al. v. Apotex Corp., et al.* (D.N.J. Nov. 10, 2015) is related to the matter in controversy because the matter in controversy involves the same patents and defendants who filed Abbreviated New Drug Applications seeking to market generic versions of the same drug product.

I further certify that, to the best of my knowledge, the matter in controversy is not the subject of any other action pending in any court or of any pending arbitration or administrative proceeding.

Dated: November 11, 2015

By: s/ Charles M. Lizza

Charles M. Lizza
William C. Baton
SAUL EWING LLP
One Riverfront Plaza, Suite 1520
Newark, New Jersey 07102-5426
(973) 286-6700
clizza@saul.com

Of Counsel:

F. Dominic Cerrito
Eric C. Stops
Evangeline Shih
Gabriel P. Brier
Catherine T. Mattes
Brian J. Forsatz
QUINN EMANUEL URQUHART & SULLIVAN, LLP
51 Madison Avenue, 22nd Floor
New York, New York 10010
(212) 849-7000

Robert Green
Caryn Borg-Breen
GREEN, GRIFFITH & BORG-BREEN LLP
NBC Tower, Suite 3100
455 North Cityfront Plaza Drive
Chicago, Illinois 60611
(312) 883-8000

*Attorneys for Plaintiffs
Dexcel Pharma Technologies Ltd.
and Dexcel Ltd.*

EXHIBIT A

US009023391B2

(12) **United States Patent**
Lahav et al.(10) **Patent No.:** **US 9,023,391 B2**
(45) **Date of Patent:** ***May 5, 2015**(54) **STABLE BENZIMIDAZOLE FORMULATION**(75) Inventors: **Raffael Lahav**, Qiriat Bialik (IL); **Erica Lahav**, legal representative, Qiriat Bialik (IL); **Valerie Azoulay**, Pardes Hana (IL)(73) Assignee: **Dexcel Ltd.**, Or-Akiva (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1882 days.

This patent is subject to a terminal disclaimer.

5,817,338	A *	10/1998	Bergstrand et al.	424/468
5,879,708	A	3/1999	Makino	
6,013,281	A	1/2000	Lundberg	
6,017,560	A	1/2000	Makino	
6,077,541	A	6/2000	Chen	
6,096,340	A	8/2000	Chen	
6,123,962	A	9/2000	Makino	
6,149,942	A	11/2000	Scheiwe	
6,174,548	B1 *	1/2001	Chen et al.	424/474
6,228,400	B1	5/2001	Lee	
6,245,351	B1	6/2001	Nara	
6,262,085	B1	7/2001	Whittle	
6,268,385	B1	7/2001	Whittle	
6,296,875	B1	10/2001	Makino	
6,326,384	B1	12/2001	Whittle	
6,380,234	B1	4/2002	Makino	
6,521,256	B2	2/2003	Makino	

(Continued)

(21) Appl. No.: **11/785,300**(22) Filed: **Apr. 17, 2007**

FOREIGN PATENT DOCUMENTS

(65) **Prior Publication Data**

US 2007/0196485 A1 Aug. 23, 2007

DE	19626045	1/1998
EP	5129 B1	10/1979

(Continued)

Related U.S. Application Data

(60) Division of application No. 10/018,992, filed on Feb. 19, 2003, now Pat. No. 7,255,878, which is a continuation-in-part of application No. PCT/IL00/00364, filed on Jun. 21, 2000.

(30) **Foreign Application Priority Data**

Jun. 22, 1999 (IL) 130602

(51) **Int. Cl.**

A61K 9/00	(2006.01)
A61K 9/14	(2006.01)
A61K 31/4439	(2006.01)
A61K 9/24	(2006.01)
A61P 1/04	(2006.01)
B05D 7/00	(2006.01)
A61K 31/4184	(2006.01)
A61K 9/20	(2006.01)
A61K 9/28	(2006.01)
A61K 9/50	(2006.01)

(52) **U.S. Cl.**CPC **A61K 31/4184** (2013.01); **A61K 9/2031** (2013.01); **A61K 9/284** (2013.01); **A61K 9/2866** (2013.01); **A61K 9/5078** (2013.01); **A61K 31/4439** (2013.01)(58) **Field of Classification Search**CPC . A61K 9/2031; A61K 9/284; A61K 31/4439; A61K 9/5078; A61K 31/4184; A61K 9/2866
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

5,045,321	A	9/1991	Makino	
5,093,132	A	3/1992	Makino	
5,225,202	A *	7/1993	Hodges et al.	424/480
5,433,959	A	7/1995	Makino	
5,508,276	A *	4/1996	Anderson et al.	514/183
5,536,735	A *	7/1996	Takechi et al.	514/338
5,639,478	A	6/1997	Makino	
5,690,960	A *	11/1997	Bengtsson et al.	424/480

Organic, "Organic", printed on: Aug. 23, 2014, accessed from: <http://www.businessdictionary.com/definition/organic.html>, pp. 1.*

ISR of parent PCT application, Dec. 2000.

IPER of parent PCT application, Dec. 2001.

Search Report for corresponding European application EP1187599, Jun. 2004.

Response to office action for corresponding European application EP1187599 on Mar. 22, 2005.

Response to office action for corresponding European application EP1187599 on Aug. 8, 2006.

Response to office action for corresponding European application EP1187599 on Apr. 23, 2007.

(Continued)

Primary Examiner — Michael G Hartley*Assistant Examiner* — Lance Rider(74) *Attorney, Agent, or Firm* — Pabst Patent Group LLP(57) **ABSTRACT**

A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage is no longer acidic.

14 Claims, No Drawings

US 9,023,391 B2

Page 2

(56)

References Cited**U.S. PATENT DOCUMENTS**

6,602,522	B1	8/2003	Chen
6,623,759	B2	9/2003	Heese
6,699,885	B2	3/2004	Phillips
6,726,927	B2	4/2004	Chen
6,733,778	B1	5/2004	Chen
6,749,864	B2	6/2004	Makino
6,780,435	B2	8/2004	Chen
6,855,336	B2	2/2005	Chen
2002/0039597	A1	4/2002	Ukai
2002/0054913	A1*	5/2002	Heese et al. 424/490
2002/0098242	A1	7/2002	Darder
2002/0128293	A1	9/2002	Rampal
2003/0091643	A1	5/2003	Friesen
2003/0175348	A1	9/2003	Kofler
2003/0228363	A1	12/2003	Patel
2003/0236285	A1	12/2003	Patel
2004/0028737	A1	2/2004	Deshpande
2004/0175427	A1	9/2004	Chen
2004/0209919	A1	10/2004	Makino
2004/0213847	A1	10/2004	Matharu
2005/0163846	A1	7/2005	Aoki

FOREIGN PATENT DOCUMENTS

EP	0124495	B1	11/1984
EP	237200	B1	9/1987
EP	519144	B1	12/1992
FR	2692146		12/1993
GB	2189698		11/1987
WO	WO8300435	A1	2/1983
WO	WO 9637195		11/1996
WO	WO 9712581		4/1997
WO	WO 9800114		1/1998
WO	WO 9840069	A2 *	9/1998
WO	WO 9925323		5/1999
WO	WO 9927917		6/1999
WO	WO 0012064		3/2000
WO	WO 0078284		12/2000

WO	WO 0124777	4/2001
WO	WO 0211699	2/2002
WO	WO 0219991	3/2002
WO	WO 02102356	12/2002
WO	WO 03024449	3/2003
WO	WO 03072087	9/2003
WO	WO 03077888	9/2003
WO	WO 03103638	12/2003
WO	WO 04000279	12/2003
WO	WO 2004014345	2/2004
WO	WO 2004050058	6/2004
WO	WO 2004050068	6/2004
WO	WO 2004089333	10/2004

OTHER PUBLICATIONS

Office action for corresponding European application EP1187599 on Mar. 22, 2005.

Office action for corresponding European application EP1187599 on Aug. 8, 2006.

Office action for corresponding European application EP1187599 on Apr. 23, 2007.

Heinamaki J T et al: "Comparative evaluation of ammoniated aqueous and organic-solvent-based cellulose ester enteric coating systems: a study on free films". Int J Pharmaceutics Elsevier BV NL. vol. 109(1) pp. 9-16 XP025592048, Aug. 22, 1994.

Hilton A.K. Deasy P.B. "Use of hydroxypropyl methylcellulose acetate succinate in an enteric polymer matrix to design controlled-release tablets of amoxicillin trihydrate" J. Pharm. Sciences vol. 82(7) 1993 pp. 737-743 XP002156064.

Lin F et al "The dissolution kinetics of brucite antigorite talc and phlogopite at room temperature and pressure" American Mineralogist 1981 66 801-6.

Pilbrant and C. Cederberg Scan. J. Gastroenterol. 20: 113-120 1985. J.W. Stafford et al. Drug Development and Industrial Pharmacy 8:513-530 1982.

"The In Vitro and In Vivo Performance of Aqueous Based Enteric Coats of Neutralized Hydroxypropyl Methyl Cellulose Phthalate" (J.R. Bloor et al. Drug Development and Industrial Pharmacy 15:2227-2243 1989.

* cited by examiner

US 9,023,391 B2

1

STABLE BENZIMIDAZOLE FORMULATION

This Application is a Divisional Application of application Ser. No. 10/018,992 filed on Feb. 19, 2003 (now U.S. Pat. No. 7,255,878), which is a Continuation-in-Part Application of PCT Application No. PCT/IL00/00364 filed on Jun. 21, 2000, and also claims priority from Israeli Patent Application No. 130602 filed on Jun. 22, 1999, all of which are hereby incorporated by reference as if fully set forth herein.

FIELD AND BACKGROUND OF THE INVENTION

The present invention relates to a novel stable formulation for an acid labile benzimidazole, and methods of preparation and administration thereof, and in particular, for a stable formulation of a benzimidazole which is suitable for oral administration.

Omeprazole, Pantoprazole, Lansoprazole and other derivatives of benzimidazole, which are active proton pump inhibitors and used conventionally for decreasing gastric secretion are known to be susceptible to degradation and transformation in acid media. Omeprazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, is disclosed and described in European Patent No. 5129 and European Patent No. 124495, as well as in numerous other patents and published patent applications.

The susceptibility of these active proton pump inhibitor substances to degradation and transformation in acid media increases the difficulty of preparing a pharmaceutical form designed for oral administration. If the active substance comes into contact with the stomach content, which is a highly acidic medium, these chemical substances become degraded. Thus, these benzimidazole derivatives should be protected both during storage and during their passage through the acidic environment of the stomach.

The stability of Omeprazole has been extensively studied (see for example A. Pilbrant and C. Cederberg, *Scand. J. Gastroenterol.*, 20: 113-120, 1985). Omeprazole degrades with a half-life of less than 10 minutes in an environment with pH values below 4.0. At pH 6.5, the half life of Omeprazole is 18 hours and at pH 11 about 300 days. Therefore, the environment of Omeprazole should be kept at a sufficiently high pH value in order to maintain the stability of the compound, in a formulation which is suitable as a product for oral administration, for example by locating Omeprazole within a core which also contains alkaline constituents. This leads to an alkaline reaction aimed at improving stability of the active substance during manufacture thereof and during storage of the pharmaceutical formulation.

In addition, such a formulation must protect Omeprazole from the acidic environment of the stomach, since if Omeprazole is given orally without any protective coating, it will degrade in the acid environment of the stomach. European Patent No. 237,200 discloses one solution, which is to directly coat the solid core containing Omeprazole, or another benzimidazole derivative, with an enteric coating layer.

However, this apparent solution to the instability of Omeprazole caused further complications, in that the alkaline core containing Omeprazole was found to react with the enteric coating, thereby causing the enteric coating to degrade. A solution to these further complications is disclosed in United Kingdom Patent Application No. 2,189,698, in which Omeprazole is contained within a solid active core, which is coated first with a subcoating layer and then with an enteric coating layer. The enteric coating layer protects the Omeprazole during the passage through the stomach, while the subcoating

2

layer protects the enteric coating layer from reacting negatively with the alkaline core containing Omeprazole.

The background art describes other attempts to provide formulations which are suitable for oral administration of acid-labile substances. For example, PCT Application No. WO 97/12581 discloses a composition adapted for oral administration containing Omeprazole which specifically does not include alkaline-reacting compounds. Instead, the composition features a core composed of a nuclei and Omeprazole compressed together, an intermediate layer and an enteric layer.

European Patent Application No. 519,144 discloses a formulation for Omeprazole, which features a neutral (sugar) core. Omeprazole is sprayed onto the sugar core, after which an intermediate coating layer and an enteric coating layer are sprayed onto the core.

PCT Application No. WO 98/00114 discloses a modification to other background art formulations for Omeprazole, in which the intermediate subcoating layer is partially neutralized with an alkaline compound. However, this modified formulation still features the subcoating layer, which is a disadvantage in that it complicates the manufacturing process and increases the expense and difficulty of manufacture. Thus, the formulation disclosed in PCT Application No. WO 98/00114, like those disclosed in European Patent Application No. 519,144 and other background art references, has the disadvantage of requiring the intermediate layer.

PCT Application No. WO 83/00435 discloses a solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH 7. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. In contrast to the present invention, Omeprazole is not disclosed as one of the active agents.

French Application No. 2,692,146 discloses stable compositions of microgranules of gastro-protected Omeprazole. The composition features a center of Omeprazole diluted in mannitol. This center is coated with an intermediate layer featuring mannitol. An enteric coating is then added over this intermediate layer. PCT Application No. WO 97/12581 discloses a formulation in which an intermediate layer between the core and an enteric coating contains silicon dioxide.

PCT Application No. WO 96/37195 discloses a formulation which lacks a subcoating layer, but which features a core containing titanium dioxide. Both the core containing Omeprazole and the enteric coating layer placed on top of the core include titanium dioxide as an ingredient. Unfortunately, titanium dioxide is only able to mask the discoloration caused by the reaction between Omeprazole and the enteric coating layer, but cannot prevent such an undesirable reaction. Thus, the disclosed formulation does not prevent the undesirable reaction between the benzimidazole derivative and the enteric coating, which is known in the art.

German Patent Application No. 196 26 045 A1 discloses a method for stabilising Omeprazole by coating small tablets or pellets, containing large amounts of mannitol, with a subcoating of Eudragit L. The subcoating of Eudragit L is neutralized, after which a final enteric coat of non-neutralized Eudragit L is applied.

A formulation of a benzimidazole derivative, such as Omeprazole, which lacks an intermediate coating layer and yet which is stable both during storage and during the passage through the stomach, would be highly desirable. Such a formulation would be simpler to manufacture and would expose the sensitive benzimidazole derivative to fewer production

US 9,023,391 B2

3

steps, thereby decreasing the possibility that the active compound would degrade during production. Unfortunately, such a stable benzimidazole formulation, which lacks an intermediate layer, is not currently available.

There is thus a unmet need for, and it would be useful to have, a stable benzimidazole formulation, particularly for Omeprazole which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach.

SUMMARY OF THE INVENTION

The formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material.

The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach, where the acidic environment of the stomach causes a partial ionic exchange to occur within the material of the coating. This partial ionic exchange renders the coating impermeable to the acidic liquids of the stomach. On the other hand, during storage the problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the "enteric coat" is no longer acidic during the storage period.

Preferably, the benzimidazole derivative is selected from the group consisting of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, and pharmaceutically acceptable salts thereof, as well as any other derivatives of benzimidazole which are proton pump inhibitors and which are conventionally used to decrease gastric secretion.

According to the present invention, there is provided a stable composition for a benzimidazole derivative, the composition comprising: (a) a substrate, the substrate featuring the benzimidazole derivative; and (b) an enteric coating material layered over the substrate, the enteric coating material having a pH value of at least about 6.5.

The substrate can optionally have several different structures. For example, the substrate is optionally an active core containing the benzimidazole derivative, in which the core is a pellet, bead or tablet for example. The active core can be prepared by any conventional method known in the art, including but not limited to, pellets prepared by spheronisation, pellets prepared by coating an inert non pareil seed with Omeprazole, tablets prepared by granulation and compression, as well as any other methods.

The enteric coating material optionally and preferably includes an enteric material selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methyl methacrylate and polymethacrylic acid ethyl methacrylate.

More preferably, the enteric coating material further comprises an alkaline compound, such that the pH value is adjusted by adding the alkaline compound to the enteric

4

material. Most preferably, the alkaline compound is an inorganic or organic alkaline salt compound. Even more preferably, the alkaline compound is selected from the group consisting of basic sodium, potassium or ammonium hydroxide. Also most preferably, the pH value is in a range of from about 7 to about 10.

The enteric coating material of the composition could optionally include a plasticizer. Preferably, the plasticizer is selected from the group consisting of a citric acid ester and a phthalic acid ester.

According to another embodiment of the present invention, there is provided a stable composition for a benzimidazole derivative, the composition consisting essentially of: (a) a substrate, the substrate featuring the benzimidazole derivative; and (b) an enteric coating material layered over the substrate, the enteric coating material having a pH value of at least about 6.5.

According to still another embodiment of the present invention, there is provided a method for producing a stable composition for a benzimidazole derivative, the method comprising the steps of: (a) forming a substrate with the benzimidazole derivative; (b) preparing an enteric coating material having a pH value of at least about 6.5; and (c) layering the enteric coating material over the substrate.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material.

The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage is no longer acidic.

Without wishing to be limited to a single mechanism, it is hypothesized that as the formulation passes through an acidic environment, such as the acidic environment of the stomach, the outer layer of the enteric coat is converted to an acidic form. This acidic form of the enteric coating material is insoluble in the acidic environment of the stomach. If the formulation is then placed in an environment with a more alkaline pH value, for example by moving into the small intestine, the enteric coat dissolves and releases the active substance.

The use of an enteric coating which includes HPMCP (hydroxypropylmethylcellulose phthalate) neutralized with a basic salt is disclosed in U.S. Pat. No. 5,225,202 and in two scientific articles, "Enteric Film Coating Using Completely Aqueous Dissolved Hydroxypropyl Methyl Cellulose Phthalate Spray Solutions" (J. W. Stafford et al., *Drug Development and Industrial Pharmacy*, 8:513-530, 1982) and "The In Vitro and In Vivo Performance of Aqueous Based Enteric Coats of Neutralized Hydroxypropyl Methyl Cellulose Phthalate" (J. R. Bloor et al., *Drug Development and Industrial Pharmacy*,

US 9,023,391 B2

5

15:2227-2243, 1989). However, the disclosed enteric coating is not taught or suggested in any of these references as a suitable direct enteric coating for substrates which contain Omeprazole. As noted previously, Omeprazole and the related benzimidazole derivatives are unusually sensitive molecules, and as such must be carefully protected. Furthermore, U.S. Pat. No. 5,225,202 teaches the necessity for a subcoat between the drug-containing substrate and the enteric coating for drugs which are not compatible with the enteric coating. By contrast, the present invention has been shown to be highly effective without such a subcoat, which is particularly surprising since the background art teaches that formulations containing Omeprazole or another benzimidazole derivative must also feature a subcoat. Neither scientific article even considers the problems associated with acid-sensitive drugs, and as such cannot teach or suggest the formulation of the present invention.

As shown by both the in vitro and in vivo data given below, the formulation of the present invention has been shown to be particularly effective for the oral administration of Omeprazole as the exemplary benzimidazole derivative, a result which could not have been predicted from these references. Indeed, the article by J. R. Bloor et al. teaches away from the use of such a neutralized enteric coating for any formulation, as this article disclosed good in vitro performance of the formulation but poor in vivo performance. By contrast, as described in greater detail below with regard to Example 7, the formulation of the present invention shows good performance in vivo. Thus, the background art neither teaches nor suggests the direct coating of a substrate containing Omeprazole or another benzimidazole derivative with an enteric coating material having a pH value of at least about 6.5, and in fact teaches away from such a formulation.

The preparation of the benzimidazole-containing compositions of the present invention is described first with reference to the following general description and then with reference to the following non-limiting examples of the preparation and application of the compositions of the present invention.

As noted previously, the formulation of the present invention includes a substrate which features the benzimidazole derivative. A solution is prepared with the enteric coating material, which has a pH value of at least 6.5 and more preferably of from about 7 to about 10. Preferably, a pH value in the desired range is obtained by adding an alkaline compound to an enteric coating material. More preferably, the alkaline compound is selected from the group consisting of sodium, potassium or ammonium hydroxide. This enteric coating solution is then layered directly over the substrate to form the composition of the present invention.

The term "substrate" refers to substantially any structure which features the benzimidazole derivative, such as Omeprazole. For example, this structure could be an active core containing the benzimidazole derivative. This active core could be prepared in a number of different ways which are known in the art. For example, the active core could be formed by compressing the benzimidazole derivative with an alkaline substance. As another example, the active core could be prepared by mixing the benzimidazole derivative with an alkaline substance, spheronizing the mixture and then forming cores through pelletisation. As yet another example, the active core is optionally and preferably prepared by embedding the active ingredient in a poloxamer and compressing the embedded material into tablets. The active core is also optionally formed by granulating the active ingredient with an alkaline substance and compressing the granulation into tablets.

6

Alternatively and optionally, the structure could include a neutral core, such as a sugar bead which does not contain the benzimidazole derivative, over which the benzimidazole derivative is coated. The coating includes Omeprazole or other benzimidazole derivative with a suitable adhesive polymer.

The substrate optionally and preferably includes a basic stabilizing material, which is more preferably at least one of sodium stearate and arginine, particularly for the active coating. Magnesium carbonate and/or sodium hydrogen carbonate may also optionally be used as basic stabilizing materials, in addition to, or alternatively in place of, these materials.

Substantially any type of neutralized suitable enteric coating material could be used in order to coat the benzimidazole substrate, including but not limited to, cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; polymethacrylic acid methyl methacrylate or ethyl methacrylate, such as the various types of Eudragit; and hydroxypropyl methylcellulose acetate succinate (HPM-CAS). However, preferably the enteric coating material is prepared with the proviso that this material does not contain HPMCP alone, but only in combination with at least one of these other listed enteric coating materials. More preferably, HPMCP is not present in the enteric coating material. The particularly preferred enteric coating material is HPMCAS.

As used herein, the term "neutralized enteric coating material" refers to enteric coating material which has been at least partially neutralized by reaction with an alkaline compound, which is optionally a basic inorganic salt. Preferably, the enteric coating material is at least about 60% neutralized, more preferably the enteric coating material is at least about 80% neutralized, and most preferably the enteric coating material is at least about 95% neutralized.

The enteric coating optionally contains a plasticizer, such as a citric acid ester, a phthalic acid ester, or any suitable plasticizer.

The method for applying the enteric coating material to the substrate can vary. Substantially any coating method can be used, such as pan coating or fluidized bed coating, with the solution of the enteric coat chosen. As noted previously, preferably this solution is an aqueous solution. The enteric coating materials described previously can be applied to the substrate in an aqueous solution if the pH value of the solution is adjusted to at least 6.5, and more preferably to an alkaline value, most preferably a pH value from about 7 to about 10.

The following specific examples illustrate various aspects of the compositions of the present invention, and are not intended to be limiting in any way. Specific reference is made to Omeprazole for the purposes of description only and without intending to be limiting.

EXAMPLE 1

This example of the composition of the present invention was prepared as follows. The substrate was in the form of an active core, which was prepared by embedding Omeprazole in poloxamer (Pluronic PE 6800), granulating the resulting mass, adding the necessary auxiliary substances to the mass, and compressing the resultant material into tablets. The substrate was then coated with alkaline polyvinyl acetate phthalate as the enteric coating layer.

US 9,023,391 B2

7

Substrate (Active Embedded Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	12 mg
Titanium dioxide	100 mg
Ludipress ®	226 mg
Sodium stearyl fumarate	25 mg

Enteric coating layer	
Polyvinyl acetate phthalate	75 mg
Antifoam emulsion	0.25 mg
Sodium hydroxide	12 mg

For the preparation of the substrate, the poloxamer was melted at a temperature of 80° C. Omeprazole, together with 2 mg colloidal silicon dioxide, 8 mg of magnesium carbonate, titanium dioxide and 6 mg of sodium starch glycolate were added and mixed thoroughly. Mixing was continued until the melt solidified. The melt was granulated and the rest of the ingredients added to the granulate. The granulate was then compressed into tablets which contained 20 mg Omeprazole. These tablets, which formed the substrate of the composition, were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared in the following manner. First, the antifoam emulsion was dissolved in water to form an aqueous solution. Polyvinyl acetate phthalate was then stirred into this solution for a final concentration of about 10% weight per volume before sodium hydroxide was added. Sodium hydroxide (1 M solution) was then added to adjust the pH value of the solution to about 8, thereby obtaining a basic solution of the enteric coating material. This solution was then sprayed onto the tablets with an incoming air temperature of 40° C.

EXAMPLE 2

This example of the composition of the present invention was prepared as follows. The substrate was prepared by embedding Omeprazole in poloxamer (Pluronic PE 6800) to form tablets, as for Example 1. However, in this Example, the tablets were then coated with hydroxypropyl methylcellulose acetate succinate (HPMCAS) as the enteric coating layer.

Substrate	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Sodium starch glycolate	20 mg
Ludipress ®	228 mg
Sodium stearyl fumarate	25 mg

Enteric coating layer	
Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS)	43 mg

8

-continued

Enteric coating layer	
Triethyl citrate	12 mg
Sodium lauryl sulfate	1.3 mg
Talc	21.4 mg
Sodium hydroxide	2.3 mg

The tablets were prepared as for Example 1, except that titanium dioxide was omitted. The tablets were then coated in a conventional coating pan with the enteric coating solution, which was prepared as follows. First, triethyl citrate was dissolved in water to form an aqueous solution. Sodium lauryl sulfate was then added to this aqueous solution. The HPM-CAS and talc were dispersed in this solution, such that the concentration of HPMCAS was about 10% weight per volume. Sodium hydroxide (1M solution) was then added to adjust the pH value of the solution to a value from about 7 to about 10. The enteric coating was layered over the substrate by spraying the solution with an incoming air temperature of 40° C.

EXAMPLE 3

This example of the composition of the present invention was prepared as for Example 1, except that the enteric coating contained alkaline HPMCP (hydroxypropylmethylcellulose phthalate) rather than HPMCAS.

Substrate	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Sodium starch glycolate	10 mg
Titanium dioxide	83 mg
Ludipress ®	145 mg
Sodium stearyl fumarate	25 mg

Enteric coating layer	
HPMC Phthalate (HP-55)	56.2 mg
Triethyl citrate	22.5 mg
Sodium hydroxide	9 mg

The substrate was prepared as described in Example 1, and was then coated in a conventional coating pan with the enteric coating solution by spraying the solution at an incoming air temperature of 40° C. The enteric coating solution was prepared as follows. The HPMC phthalate was suspended in the water to a concentration of about 10% weight per volume (before sodium hydroxide was added). Sodium hydroxide (1M solution) was then added to this aqueous suspension until the HPMCP dissolved. The resultant solution has a pH value in a range of from about 8 to about 10. The triethyl citrate was then added to the resultant solution in order to form the enteric coating solution, which was then layered over the substrate as previously described.

EXAMPLE 4

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer containing the active ingredient, which was layered over the

US 9,023,391 B2

9

neutral core. The substrate was then coated with the enteric coating solution. Hard gelatin capsules were then filled with the resultant pellets.

Substrate	
Neutral core	Quantity per capsule
Sugar spheres 20/25 (700-850 microns)	161.63 mg
Active coating	
Ingredients	Quantity per capsule
Omeprazole	20.00 mg
Hydroxypropyl methylcellulose 2910	5.33 mg
Hydroxypropyl cellulose	6.00 mg
Lactose	8.00 mg
Disodium phosphate anhydrous	0.64 mg
Sodium lauryl sulfate	0.50 mg
Enteric coating layer	
HPMCAS	21.00 mg
Triethyl citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
Talc	11.00 mg
Sodium hydroxide	1.12 mg

The composition of the present invention was prepared according to this Example as follows. First, sugar spheres were placed in a fluid bed coating chamber, equipped with a Wurster bottom spraying device. A suspension of the ingredients in water was then prepared so that the concentration was approximately 20% of total solids in water. This active coating suspension was sprayed onto the sugar spheres. A suspension of the enteric coating was prepared according to Example 2. This enteric coating was then sprayed onto the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 5

This example of the composition of the present invention was prepared with a compressed tablet as the substrate. The tablet was then coated with alkaline HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate) as the enteric coating layer, preferably having a pH in a range of from about 7 to about 10.

Substrate (Active Compressed Tablet Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	192.5 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	10 mg
Povidone	10 mg
Sodium stearyl fumarate	7.5 mg

10

Enteric coating layer	
HPMCAS	16.1 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.04
Sodium hydroxide	0.86 mg

For the preparation of the substrate, Omeprazole, together with lactose, magnesium carbonate, sodium starch glycolate, and povidone were mixed thoroughly. The mixture was then granulated with a sufficient quantity of water, and dried. Sodium stearyl fumarate was then added to the mixture, which was then compressed into tablets weighing 250 mg each.

These tablets, which formed the substrate of the composition, were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 6

Stability tests were performed with formulations prepared according to Examples 2 and 3. For the first test, both coated and uncoated tablets prepared according to either Example 2 or Example 3 were placed into a box which was open to the environment. The open box was then stored at 40° C. and 75% relative humidity, which are very stringent conditions. The coated and uncoated tablets were examined initially, after a week and after a month to determine stability. The results are shown in the tables below.

Tablets Prepared According to Example 2			
Sampled Material	Appearance of Sample		
	Initial	After One Week	After One Month
coated tablet	off white	deeper off white	deeper off white
uncoated tablet	white	white	white

Tablets Prepared According to Example 3			
Sampled Material	Appearance of Sample		
	Initial	After One Week	After One Month
coated tablet	off white	off white	deeper off white
uncoated tablet	white	white	white

The term "deeper off white" refers to a more intense off white color which was observed for some samples, as described in greater detail above. These results show that coated tablets prepared according to either Example 2 or Example 3 showed good stability, even after one month of storage under particularly stringent conditions.

In a second stability test, coated tablets were prepared according to Example 2. These coated tablets were then packed into an Alu/Alu (Aluminum/Aluminum) blister, which is a well known technique in the art for packing certain oral dosage forms. The blister was then stored under accelerated conditions of 30° C. and 60% relative humidity; or 40° C. and 75% relative humidity. Samples of the tablets were examined initially, and after one month of storage under one of these conditions. In addition, samples were assayed to determine the amount of Omeprazole present in the coated tablet,

US 9,023,391 B2

11

as listed under "Assay" as milligrams of Omeprazole per tablet. A dissolution test was performed, using the accepted USP method. The coated tablets were placed in 0.1 N HCl for 2 hours, followed by a solution at pH 6.8 with stirring with a paddle at 100 rpm for 15 minutes, 30 minutes or 45 minutes. Gastric resistance was also examined by placing the coated tablets in a simulated gastric fluid for 2 hours (pH of approximately 1), as is well known in the art. The results are shown in the table below.

	Time (min)	Initial	30° 60% RH	40° 75% RH
Description	NA	Off white	Off white	Off white
Assay	NA	20.4 mg	19.39 mg	19.66 mg
Dissolution	120	0%	0%	0%
	135	52%	42%	39%
	150	96%	85%	90%
	165	105%	99%	104%
Gastric Resistance	NA	101%	98%	96%

These results show that the coated tablets, prepared according to Example 2, show good stability and gastric resistance, yet are also able to dissolve in an appropriate time-dependent manner.

EXAMPLE 7

A one-way pharmacokinetic pilot study was performed in vivo for testing the pharmacokinetic profile of the coated tablets, which were prepared according to Example 2. The study was performed with ten healthy male volunteers, who received a single dosage of the coated tablets, containing 20 mg of Omeprazole. The results showed that Omeprazole administered in the coated tablets of the present invention had a similar lag time to absorption in comparison to a previous study performed with the reference product, which is the 20 mg Omeprazole dosage form of the formulation of Astra (Aktiebolaget Hassle), and also as described in the literature (see for example Duvauchelle, T. et al., "Comparative Bioavailability Study of Two Oral Omeprazole Formulations After Single and Repeated Administrations in Healthy Volunteers", *Pharmacokinetics*, 16: 141-149, 1998). The lag time to absorption is defined as the time between the administration of the formulation and the first detection of the active ingredient in the samples taken from the subject, according to the sampling method employed.

In addition, comparable bioavailability was achieved with the coated tablets of the present invention, both to values obtained in the previous study with the reference product and to values which were described in the literature (see for example the previously referenced article in *Pharmacokinetics*). Furthermore, the values obtained for C_{max} and T_{max} concerning the rate of absorption were comparable to results obtained in the previous study performed with the reference product, and as described in the literature (see for example the previously referenced article in *Pharmacokinetics*). Thus, the coated tablets of the present invention clearly show good performance both in vitro, as described in Example 6, and in vivo.

EXAMPLE 8

Coated pellets were prepared according to the process previously described above in Example 4. However, the pellets were coated with the following suspension:

12

Enteric coating (quantities per capsule)

HPMCAS	21.00 mg
Triethyl Citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
Colloidal silicon dioxide	2.10 mg
Sodium hydroxide	1.12 mg

EXAMPLE 9

Although the previous Examples used aqueous solutions for providing an optimal coating, the possibility of increasing the concentration of the enteric coating polymer by using an alcohol-based solution was studied in this Example.

Coated pellets were prepared according to the process of Example 4, except that these pellets were coated with the following solution, to obtain the required protection in an acidic environment.

Enteric coating

Solution prepared Quantities per capsule

Alcohol 95%	1.900 kg	N/A
Water	0.830 kg	N/A
HPMCAS	0.476 kg	21.00 mg
Triethyl citrate	0.136 kg	6.00 mg
Sodium lauryl sulfate	0.015 kg	0.66 mg
Colloidal silicon dioxide	0.047 kg	2.1 mg
Sodium hydroxide	0.025 kg	1.12 mg

EXAMPLE 10

Substrate (Active Compressed Tablet Core)

Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

Enteric coating layer

Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™ (pink pigment)	10.8 mg

For the preparation of the substrate, Omeprazole was mixed together thoroughly with lactose, sodium starch glycolate, magnesium carbonate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4, with the addition of a pigment to the enteric coating material.

US 9,023,391 B2

13

EXAMPLE 11

Stability tests were performed with the formulation prepared according to Example 10. For the tests, the tablets were packed into alu-alu blister. The blister was then stored under room temperature or under accelerated conditions of 30° C. and 60% relative humidity (RH), or 40° C. and 75% relative humidity. Samples of the tablets were examined initially and after 6 months of storage under one of these conditions. In addition samples were assayed. A dissolution test was performed, and gastric resistance was also examined. The tablet gave good stability results even after storage at 40° C. The results are shown in the table below.

Test performed	Initial	25° C.	30° C./	40° C./
		6 month	60% RH 6 month	75% RH 6 month
Visual Description	conform	conform	conform	conform
Assay	19.76 mg per tablet	20.19 mg per tablet	19.97 mg per tablet	19.28 mg per tablet
Dissolution	96%	96%	96%	96%
Gastric Resistance	96%	96%	95%	94%

EXAMPLE 12

A two-way pharmacokinetic study was performed in vivo for testing the bioequivalence of the coated tablets which were prepared according to Example 10, as compared to the reference product which is the 20 mg Omeprazole dosage form of the formulation of Astra (Sweden), called Losec™. The study was performed on 39 volunteers. As shown in the table below, the results of the study showed that the two products exhibited very similar pharmacokinetic profiles, such that the two formulations can be considered to be bioequivalent.

Formulation	AUC (ng × hour/ml)	Cmax (ng/ml)	Tmax (hours)
Formulation of the present invention (Example 10)	426 ± 256	217 ± 109	1.08 ± 0.64
Losec™ (Astra)	434 ± 226	246 ± 113	1.56 ± 0.79

EXAMPLE 13

Substrate (Active Compressed Tablet Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Sodium hydrogen carbonate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

14

Enteric coating layer

Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™	10.8 mg

For the preparation of the substrate, Omeprazole was thoroughly mixed together with lactose, sodium starch glycolate, sodium hydrogen carbonate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 14

Substrate (Active Compressed Tablet Core)

Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Trisodium citrate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

Enteric coating layer

Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™	10.8 mg

For the preparation of the substrate, Omeprazole was mixed thoroughly together with lactose, sodium starch glycolate, trisodium citrate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 15

Stability tests were performed with the formulations prepared according to Examples 10, 13 and 14. Both coated and non-coated tablets were placed into an open box and stored at 40° C. and 75% relative humidity, which are very stringent conditions. The coated and uncoated tablets were examined initially after 1 week and again after 2 weeks to determine stability. The results are shown in the tables below.

US 9,023,391 B2

15

Tablets prepared according to Example 10			
Appearance of sample			
Sampled material	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

Tablets prepared according to Example 13			
Appearance of sample			
Sampled material	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

Tablets prepared according to Example 14			
Appearance of sample			
Sampled material	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

EXAMPLE 16

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer containing the active ingredient, which was layered over the neutral core. The substrate was then coated with the enteric coating solution. Hard gelatin capsules were then filled with the resultant pellets.

Substrate	
Neutral core	Quantity per capsule
Sugar spheres 20/25 (700-850 microns)	110 mg

Active coating	
Ingredients	Quantity per capsule
Omeprazole	20.00 mg
Hydroxypropyl methylcellulose 2910	5.00 mg
Hydroxypropyl cellulose	6.00 mg
Sodium stearate	0.13 mg
Sodium lauryl sulfate	0.50 mg

Enteric coating layer	
HPMCAS	21.00 mg
Triethyl citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
colloidal silicon dioxide	2.1 mg
Arginine	3.15 mg

The composition of the present invention was prepared according to this Example as follows. First, sugar spheres were placed in a fluid bed coating chamber, equipped with a

16

Wurster bottom spraying device. A suspension of the ingredients in water was then prepared so that the concentration was approximately 20% of the total solids in water. This active coating suspension was sprayed onto the neutral sugar spheres.

A suspension of the enteric coating was prepared as follows. First, triethyl citrate was dissolved in water to form an aqueous solution. Sodium lauryl sulfate was then added to this aqueous solution. HPMCAS and colloidal silicon dioxide were dispersed in this solution, such that the concentration of HPMCAS was about 10% weight per volume. Arginine (3% weight per volume solution) was added to adjust the pH value of the solution to a pH value in a range of from about pH 7 to about pH 9. The enteric coating was layered over the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 17

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer containing the active ingredient, which was layered over the neutral core. The substrate was then coated with the enteric coating solution. Hard gelatin capsules were then filled with the resultant pellets.

Substrate	
Neutral core	Quantity per capsule
Sugar spheres 20/25 (700-850 microns)	110 mg

Active coating	
Ingredients	Quantity per capsule
Omeprazole	20.00 mg
Hydroxypropyl methylcellulose 2910	5.00 mg
Hydroxypropyl cellulose	6.00 mg
Arginine	0.13 mg
Sodium lauryl sulfate	0.50 mg

Enteric coating layer	
HPMCAS	21.00 mg
Triethyl citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
colloidal silicon dioxide	2.1 mg
Sodium hydroxide	1.12 mg

The composition of the present invention was prepared according to this Example as follows. First, sugar spheres were placed in a fluid bed coating chamber, equipped with a Wurster bottom spraying device. A suspension of the ingredients in water was then prepared so that the concentration was approximately 20% of the total solids in water. This active coating suspension was sprayed onto the sugar spheres.

A suspension of the enteric coating was prepared according to Example 8. The enteric coating was layered over the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 18

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer

US 9,023,391 B2

17

containing the active ingredient, which was layered over the neutral core. The substrate was then coated with the enteric coating solution. Hard gelatin capsules were then filled with the resultant pellets.

Substrate	
Neutral core	Quantity per capsule
Sugar spheres 20/25 (700-850 microns)	110 mg
Active coating	
Ingredients	Quantity per capsule
Omeprazole	20.00 mg
Hydroxypropyl methylcellulose 2910	5.00 mg
Hydroxypropyl cellulose	6.00 mg
Arginine	0.13 mg
Sodium lauryl sulfate	0.50 mg
Enteric coating layer	
HPMCAS	21.00 mg
Triethyl citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
colloidal silicon dioxide	2.1 mg
Arginine	3.15 mg

The composition of the present invention was prepared according to this Example as follows. First, sugar spheres were placed in a fluid bed coating chamber, equipped with a Wurster bottom spraying device. A suspension of the ingredients in water was then prepared so that the concentration was approximately 20% of the total solids in water. This active coating suspension was sprayed onto the sugar spheres to form the substrate.

A suspension of the enteric coating was prepared according to Example 16. The enteric coating was layered over the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 19

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer containing the active ingredient, which was layered over the neutral core. The substrate was then coated with the enteric coating solution to form pellets. Hard gelatin capsules were then filled with the resultant pellets.

Substrate	
Neutral core	
Ingredients	Quantity per capsule
Sugar spheres 20/25 (700-800 microns)	110 mg

18

Active coating	
Ingredients	Quantity per capsule
Omeprazole	20 mg
Hydroxypropyl methylcellulose 2910	5 mg
Hydroxypropyl cellulose	6 mg
Sodium lauryl sulfate	0.5 mg
Arginine	0.1 mg
Enteric coating layer	
Ingredients	Quantity per capsule
Triethyl citrate	35 mg
Sodium lauryl sulfate	3.8 mg
HPMCAS	126 mg
Colloidal silicon dioxide	19 mg
Talc	17 mg
Ammonia (in a 25% solution)	3 mg

The composition of the present invention was prepared according to this example as follows. First, sugar spheres were placed in a fluid bed-coating chamber, equipped with a Wurster bottom-spraying device. Next, a suspension of the ingredients in water was then prepared for a final concentration of the total solids of approximately 15% in water, to form the active coating. This active coating suspension was sprayed onto the sugar spheres, thereby forming the substrate.

A suspension of the enteric coating was then prepared as follows. First, triethyl citrate was dissolved in water to form an aqueous solution. Sodium lauryl sulfate was then added to this aqueous solution. HPMCAS, colloidal silicon dioxide and talc were dispersed in this solution, such that the concentration of HPMCAS was about 7% weight per volume. Ammonia in a 25% solution was added to adjust the pH value in a range of from about 7 to about pH 9. The enteric coating was layered over the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 20

Substrate (active compressed tablet core)	
Ingredients	Quantity per capsule
Omeprazole	20 mg
lactose	203 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg
Enteric coating layer	
Ingredients	Quantity per capsule
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
HPMCAS	16 mg
Talc	8.14 mg
Ammonia (in a 25% solution)	0.14 mg
Sepisperse ® (pink pigment)	10.8 mg
Isopropyl alcohol	N/A
Alcohol	N/A

US 9,023,391 B2

19

The substrate of the present invention was prepared as described in Example 10. A suspension of the enteric coating was then prepared as follows. First, triethyl citrate was dissolved in a mixture of isopropyl alcohol and alcohol. Sodium lauryl sulfate was then added to this solution. HPMCAS and talc were dispersed in this solution, such that the concentration of HPMCAS was about 6% weight per volume. Ammonia in a 25% solution was added to adjust the pH value in a range of from about pH 7 to about pH 9. The pigment was then added to the enteric coating dispersion. The tablet cores were then transferred into a conventional coating pan and coated with the enteric coating layer.

EXAMPLE 21

Substrate (active compressed tablet core)	
Ingredients	Quantity per capsule
Omeprazole	10 mg
lactose	101.5 mg
Sodium stearate	5 mg
Sodium starch glycolate	5 mg
Sodium stearyl fumarate	3.5 mg

Enteric coating layer	
Ingredients	Quantity per capsule
Triethyl citrate	2.25 mg
Sodium lauryl sulfate	0.25 mg
HPMCAS	8 mg
Talc	4.7 mg
Sodium hydroxide	0.43 mg
Sepisperse ® (pink pigment)	5.4 mg

For the preparation of the substrate, Omeprazole was mixed together thoroughly with lactose, sodium starch glycolate, sodium stearate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 125 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 10.

EXAMPLE 22

Stability tests were performed with the formulation prepared according to Example 21. For the tests, the tablets were packed into alu-alu blister. The blister was then stored under room temperature or under accelerated conditions of 30° C. and 60% relative humidity (RH), or 40° C. and 75% relative humidity. Samples of these tablets were examined initially and after 6 months of storage under one of these conditions. In addition samples were assayed and purity test was performed. A dissolution test was performed, and gastric resistance was also examined. The tablet gave good stability results even after storage at 40° C. The results are shown in the table below.

Test performed	Initial	25° C. 6 months	30° C./ 60% RH 6 months	40° C./ 75% RH 6 months
Description	conform	conform	conform	conform
Assay	98.4%	96.7%	96.9%	96.3%

20

-continued

Test performed	Initial	25° C. 6 months	30° C./ 60% RH 6 months	40° C./ 75% RH 6 months
Dissolution	95%	97%	95%	95%
gastric resistance	96%	95%	97%	96%
individual impurity	0.04%	not detectable	not detectable	0.23%
total impurity	0.04%	not detectable	not detectable	0.29%

While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.

What is claimed is:

1. A stable composition for oral administration of a benzimidazole derivative, the composition consisting essentially of:

- a single tablet core consisting essentially of
 - a benzimidazole derivative;
 - sodium stearate in an amount between about 0.09% to about 4% by weight of the core which is effective to stabilize the benzimidazole derivative in the composition;
 - at least one excipient that is not a stabilizing material; and

- a single layer comprising an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate, the enteric polymer having been layered directly onto the core from a solution or dispersion having a pH of at least pH 6.5 and comprising a neutralizing agent selected from the group consisting of sodium, potassium and ammonium hydroxide.

2. The composition of claim 1, wherein the non-stabilizing excipient is selected from the group consisting of sodium stearyl fumarate, sodium starch glycolate and lactose.

3. The composition of claim 1, wherein the non-stabilizing excipient is povidone.

4. The composition of claim 1, wherein the single enteric layer further comprises a plasticizer selected from the group consisting of a citric acid ester and a phthalic acid ester.

5. The composition of claim 1, wherein the single enteric layer further comprises sodium lauryl sulfate and talc.

6. The composition of claim 1, wherein the enteric polymer is at least about 60% neutralized prior to said single layer being layered directly over the single tablet core.

7. The composition of claim 6, wherein the enteric polymer is at least about 80% neutralized prior to said single layer being layered directly over the single tablet core.

8. The composition of claim 7, wherein the enteric polymer is at least about 95% neutralized prior to said single layer being layered directly over the single tablet core.

9. The composition of claim 1, wherein the single enteric layer further comprises one or more of a glidant, coloring agent or polishing agent.

10. The composition of claim 1, wherein the benzimidazole derivative is selected from the group consisting of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, and pharmaceutically acceptable salts thereof.

US 9,023,391 B2

21

11. The composition of claim 1, wherein the single tablet core comprises an active core for containing the benzimidazole derivative.

12. The composition of claim 1, wherein the active core is a tablet formed by compression. 5

13. A stable tablet composition for oral administration of a benzimidazole derivative, the composition consisting essentially of:

a single tablet core, the single tablet core consisting essentially of the benzimidazole derivative, sodium stearate in an effective amount of about 4% by weight of the core to stabilize the benzimidazole derivative in the composition; and at least one excipient that is not a stabilizing material; and

a single layer comprising an enteric polymer consisting essentially of neutralized HPMCAS, said HPMCAS having been neutralized to a pH of at least 6.5 by an alkalizing agent comprising ammonium hydroxide, the single layer layered directly over said single tablet core. 15

14. The composition of claim 1, wherein the sodium stearate is present in the core in an amount of about 4% by weight of the core. 20

* * * * *

22

EXHIBIT B



US007255878B1

(12) **United States Patent**
Lahav et al.

(10) **Patent No.:** **US 7,255,878 B1**
(45) **Date of Patent:** **Aug. 14, 2007**

(54) **STABLE BENZIMIDAZOLE FORMULATION**

(75) Inventors: **Raffael Lahav**, deceased, late of Quiriat Bialik (IL); by **Erica Lahav**, legal representative, Quiriat Bialik (IL); **Valerie Azoulay**, Pardes Hannah (IL)

(73) Assignee: **Dexcel Ltd.**, Hadera (IL)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 168 days.

(21) Appl. No.: **10/018,992**

(22) PCT Filed: **Jun. 21, 2000**

(86) PCT No.: **PCT/IL00/00364**

§ 371 (c)(1),
(2), (4) Date: **Feb. 19, 2003**

(87) PCT Pub. No.: **WO00/78284**

PCT Pub. Date: **Dec. 28, 2000**

(30) **Foreign Application Priority Data**

Jun. 22, 1999 (IL) 130602

(51) **Int. Cl.**

A61K 9/16 (2006.01)
A61K 9/00 (2006.01)
A61K 9/14 (2006.01)
A61K 9/20 (2006.01)
A61K 9/22 (2006.01)

(52) **U.S. Cl.** **424/490**; 424/400; 424/464;
424/465; 424/489; 424/493; 424/494

(58) **Field of Classification Search** 242/400,
242/464, 489, 490, 493, 494, 485
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,817,338 A * 10/1998 Bergstrand et al. 424/468

6,013,281 A * 1/2000 Lundberg et al. 424/468
6,149,942 A * 11/2000 Scheiwe et al. 424/490
6,228,400 B1 * 5/2001 Lee et al. 424/489
6,623,759 B2 * 9/2003 Heese et al. 424/480

FOREIGN PATENT DOCUMENTS

WO WO 99/27917 * 6/1999

* cited by examiner

Primary Examiner—Michael G. Hartley

Assistant Examiner—Simon J. Oh

(74) *Attorney, Agent, or Firm*—D'vorah Graeser; Dr. D. Graeser Ltd.

(57) **ABSTRACT**

A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage is no longer acidic.

33 Claims, No Drawings

US 7,255,878 B1

1

STABLE BENZIMIDAZOLE FORMULATION**FIELD AND BACKGROUND OF THE INVENTION**

The present invention relates to a novel stable formulation for an acid labile benzimidazole, and methods of preparation and administration thereof, and in particular, for a stable formulation of a benzimidazole which is suitable for oral administration.

Omeprazole, Pantoprazole, Lansoprazole and other derivatives of benzimidazole, which are active proton pump inhibitors and used conventionally for decreasing gastric secretion are known to be susceptible to degradation and transformation in acid media. Omeprazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, is disclosed and described in European Patent No. 5129 and European Patent No. 124495, as well as in numerous other patents and published patent applications.

The susceptibility of these active proton pump inhibitor substances to degradation and transformation in acid media increases the difficulty of preparing a pharmaceutical form designed for oral administration. If the active substance comes into contact with the stomach content, which is a highly acidic medium, these chemical substances become degraded. Thus, these benzimidazole derivatives should be protected both during storage and during their passage through the acidic environment of the stomach.

The stability of Omeprazole has been extensively studied (see for example A. Pilbrant and C. Cederberg, *Scan. J Gastroenterol.*, 20: 113-120, 1985). Omeprazole degrades with a half-life of less than 10 minutes in an environment with pH values below 4.0. At pH 6.5, the half life of Omeprazole is 18 hours and at pH 11 about 300 days. Therefore, the environment of Omeprazole should be kept at a sufficiently high pH value in order to maintain the stability of the compound, in a formulation which is suitable as a product for oral administration, for example by locating Omeprazole within a core which also contains alkaline constituents. This leads to an alkaline reaction aimed at improving stability of the active substance during manufacture thereof and during storage of the pharmaceutical formulation.

In addition, such a formulation must protect Omeprazole from the acidic environment of the stomach, since if Omeprazole is given orally without any protective coating, it will degrade in the acid environment of the stomach. European Patent No. 237,200 discloses one solution, which is to directly coat the solid core containing Omeprazole, or another benzimidazole derivative, with an enteric coating layer.

However, this apparent solution to the instability of Omeprazole caused further complications, in that the alkaline core containing Omeprazole was found to react with the enteric coating, thereby causing the enteric coating to degrade. A solution to these further complications is disclosed in United Kingdom Patent Application No. 2,189,698, in which Omeprazole is contained within a solid active core, which is coated first with a subcoating layer and then with an enteric coating layer. The enteric coating layer protects the Omeprazole during the passage through the stomach, while the subcoating layer protects the enteric coating layer from reacting negatively with the alkaline core containing Omeprazole.

The background art describes other attempts to provide formulations which are suitable for oral administration of

2

acid-labile substances. For example, PCT Application No. WO 97/12581 discloses a composition adapted for oral administration containing Omeprazole which specifically does not include alkaline-reacting compounds. Instead, the composition features a core composed of a nuclei and Omeprazole compressed together, an intermediate layer and an enteric layer.

European Patent Application No. 519,144 discloses a formulation for Omeprazole, which features a neutral (sugar) core. Omeprazole is sprayed onto the sugar core, after which an intermediate coating layer and an enteric coating layer are sprayed onto the core.

PCT Application No. WO 98/00114 discloses a modification to other background art formulations for Omeprazole, in which the intermediate subcoating layer is partially neutralized with an alkaline compound. However, this modified formulation still features the subcoating layer, which is a disadvantage in that it complicates the manufacturing process and increases the expense and difficulty of manufacture. Thus, the formulation disclosed in PCT Application No. WO 98/00114, like those disclosed in European Patent Application No. 519,144 and other background art references, has the disadvantage of requiring the intermediate layer.

PCT Application No. WO 83/00435 discloses a solid dosage form, such as a capsule or tablet, containing a pharmacologically active agent coated with an anionic polymer, which is insoluble in gastric juice and in intestinal juice below pH 7. The preferred anionic polymer is a partly methyl esterified methacrylic acid polymer in which the ratio of free carboxylic groups to ester groups is about 1:2. In contrast to the present invention, Omeprazole is not disclosed as one of the active agents.

French Application No. 2,692,146 discloses stable compositions of microgranules of gastro-protected Omeprazole. The composition features a center of Omeprazole diluted in mannitol. This center is coated with an intermediate layer featuring mannitol. An enteric coating is then added over this intermediate layer. PCT Application No. WO 97/12581 discloses a formulation in which an intermediate layer between the core and an enteric coating contains silicon dioxide.

PCT Application No. WO 96/37195 discloses a formulation which lacks a subcoating layer, but which features a core containing titanium dioxide. Both the core containing Omeprazole and the enteric coating layer placed on top of the core include titanium dioxide as an ingredient. Unfortunately, titanium dioxide is only able to mask the discoloration caused by the reaction between Omeprazole and the enteric coating layer, but cannot prevent such an undesirable reaction. Thus, the disclosed formulation does not prevent the undesirable reaction between the benzimidazole derivative and the enteric coating, which is known in the art.

German Patent Application No. 196 26 045 A1 discloses a method for stabilising Omeprazole by coating small tablets or pellets, containing large amounts of mannitol, with a subcoating of Eudragit L. The subcoating of Eudragit L is neutralized, after which a final enteric coat of non-neutralized Eudragit L is applied.

A formulation of a benzimidazole derivative, such as Omeprazole, which lacks an intermediate coating layer and yet which is stable both during storage and during the passage through the stomach, would be highly desirable. Such a formulation would be simpler to manufacture and would expose the sensitive benzimidazole derivative to fewer production steps, thereby decreasing the possibility that the active compound would degrade during production.

US 7,255,878 B1

3

Unfortunately, such a stable benzimidazole formulation, which lacks an intermediate layer, is not currently available.

There is thus a unmet need for, and it would be useful to have, a stable benzimidazole formulation, particularly for Omeprazole which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach.

SUMMARY OF THE INVENTION

The formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material.

The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach, where the acidic environment of the stomach causes a partial ionic exchange to occur within the material of the coating. This partial ionic exchange renders the coating impermeable to the acidic liquids of the stomach. On the other hand, during storage the problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the "enteric coat" is no longer acidic during the storage period.

Preferably, the benzimidazole derivative is selected from the group consisting of Omeprazole, Pantoprazole, Lansoprazole, Leminoprazole, Perprazole, Rabeprazole, and pharmaceutically acceptable salts thereof, as well as any other derivatives of benzimidazole which are proton pump inhibitors and which are conventionally used to decrease gastric secretion.

According to the present invention, there is provided a stable composition for a benzimidazole derivative, the composition comprising: (a) a substrate, the substrate featuring the benzimidazole derivative; and (b) an enteric coating material layered over the substrate, the enteric coating material having a pH value of at least about 6.5.

The substrate can optionally have several different structures. For example, the substrate is optionally an active core containing the benzimidazole derivative, in which the core is a pellet, bead or tablet for example. The active core can be prepared by any conventional method known in the art, including but not limited to, pellets prepared by spheronisation, pellets prepared by coating an inert non pareil seed with Omeprazole, tablets prepared by granulation and compression, as well as any other methods.

The enteric coating material optionally and preferably includes an enteric material selected from the group consisting of hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methyl methacrylate and polymethacrylic acid ethyl methacrylate.

More preferably, the enteric coating material further comprises an alkaline compound, such that the pH value is adjusted by adding the alkaline compound to the enteric material. Most preferably, the alkaline compound is an

4

inorganic or organic alkaline salt compound. Even more preferably, the alkaline compound is selected from the group consisting of basic sodium, potassium or ammonium hydroxide. Also most preferably, the pH value is in a range of from about 7 to about 10.

The enteric coating material of the composition could optionally include a plasticizer. Preferably, the plasticizer is selected from the group consisting of a citric acid ester and a phthalic acid ester.

According to another embodiment of the present invention, there is provided a stable composition for a benzimidazole derivative, the composition consisting essentially of: (a) a substrate, the substrate featuring the benzimidazole derivative; and (b) an enteric coating material layered over the substrate, the enteric coating material having a pH value of at least about 6.5.

According to still another embodiment of the present invention, there is provided a method for producing a stable composition for a benzimidazole derivative, the method comprising the steps of: (a) forming a substrate with the benzimidazole derivative; (b) preparing an enteric coating material having a pH value of at least about 6.5; and (c) layering the enteric coating material over the substrate.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The formulation of the present invention contains a benzimidazole derivative, such as Omeprazole, and is able to maintain the stability of this active ingredient without a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material.

The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach. The problem of interaction between the enteric coat and the alkaline core is thus completely eliminated as the enteric coat at this stage is no longer acidic.

Without wishing to be limited to a single mechanism, it is hypothesized that as the formulation passes through an acidic environment, such as the acidic environment of the stomach, the outer layer of the enteric coat is converted to an acidic form. This acidic form of the enteric coating material is insoluble in the acidic environment of the stomach. If the formulation is then placed in an environment with a more alkaline pH value, for example by moving into the small intestine, the enteric coat dissolves and releases the active substance.

The use of an enteric coating which includes HPMCP (hydroxypropylmethylcellulose phthalate) neutralized with a basic salt is disclosed in U.S. Pat. No. 5,225,202 and in two scientific articles, "Enteric Film Coating Using Completely Aqueous Dissolved Hydroxypropyl Methyl Cellulose Phthalate Spray Solutions" (J. W. Stafford et al., *Drug Development and Industrial Pharmacy*, 8:513-530, 1982) and "The In Vitro and In Vivo Performance of Aqueous Based Enteric Coats of Neutralized Hydroxypropyl Methyl Cellulose

US 7,255,878 B1

5

Phthalate” (J. R. Bloor et al., *Drug Development and Industrial Pharmacy*, 15:2227-2243, 1989). However, the disclosed enteric coating is not taught or suggested in any of these references as a suitable direct enteric coating for substrates which contain Omeprazole. As noted previously, Omeprazole and the related benzimidazole derivatives are unusually sensitive molecules, and as such must be carefully protected. Furthermore, U.S. Pat. No. 5,225,202 teaches the necessity for a subcoat between the drug-containing substrate and the enteric coating for drugs which are not compatible with the enteric coating. By contrast, the present invention has been shown to be highly effective without such a subcoat, which is particularly surprising since the background art teaches that formulations containing Omeprazole or another benzimidazole derivative must also feature a subcoat. Neither scientific article even considers the problems associated with acid-sensitive drugs, and as such cannot teach or suggest the formulation of the present invention.

As shown by both the in vitro and in vivo data given below, the formulation of the present invention has been shown to be particularly effective for the oral administration of Omeprazole as the exemplary benzimidazole derivative, a result which could not have been predicted from these references. Indeed, the article by J. R. Bloor et al. teaches away from the use of such a neutralized enteric coating for any formulation, as this article disclosed good in vitro performance of the formulation but poor in vivo performance. By contrast, as described in greater detail below with regard to Example 7, the formulation of the present invention shows good performance in vivo. Thus, the background art neither teaches nor suggests the direct coating of a substrate containing Omeprazole or another benzimidazole derivative with an enteric coating material having a pH value of at least about 6.5, and in fact teaches away from such a formulation.

The preparation of the benzimidazole-containing compositions of the present invention is described first with reference to the following general description and then with reference to the following non-limiting examples of the preparation and application of the compositions of the present invention.

As noted previously, the formulation of the present invention includes a substrate which features the benzimidazole derivative. A solution is prepared with the enteric coating material, which has a pH value of at least 6.5 and more preferably of from about 7 to about 10. Preferably, a pH value in the desired range is obtained by adding an alkaline compound to an enteric coating material. More preferably, the alkaline compound is selected from the group consisting of sodium, potassium or ammonium hydroxide. This enteric coating solution is then layered directly over the substrate to form the composition of the present invention.

The term “substrate” refers to substantially any structure which features the benzimidazole derivative, such as Omeprazole. For example, this structure could be an active core containing the benzimidazole derivative. This active core could be prepared in a number of different ways which are known in the art. For example, the active core could be formed by compressing the benzimidazole derivative with an alkaline substance. As another example, the active core could be prepared by mixing the benzimidazole derivative

6

with an alkaline substance, spheronizing the mixture and then forming cores through pelletisation. As yet another example, the active core is optionally and preferably prepared by embedding the active ingredient in a poloxamer and compressing the embedded material into tablets. The active core is also optionally formed by granulating the active ingredient with an alkaline substance and compressing the granulation into tablets.

Alternatively and optionally, the structure could include a neutral core, such as a sugar bead which does not contain the benzimidazole derivative, over which the benzimidazole derivative is coated. The coating includes Omeprazole or other benzimidazole derivative with a suitable adhesive polymer.

Substantially any type of neutralized suitable enteric coating material could be used in order to coat the benzimidazole substrate, including but not limited to, cellulose acetate phthalate (CAP); hydroxypropyl methylcellulose phthalate (HPMCP); polyvinyl acetate phthalate; cellulose acetate trimellitate; polymethacrylic acid methyl methacrylate or ethyl methacrylate, such as the various types of Eudragit; and hydroxypropyl methylcellulose acetate succinate (HPMCAS). However, preferably the enteric coating material is prepared with the proviso that this material does not contain HPMCP alone, but only in combination with at least one of these 7 other listed enteric coating materials. The particularly preferred enteric coating material is HPMCAS.

As used herein, the term “neutralized enteric coating material” refers to enteric coating material which has been at least partially neutralized by reaction with an alkaline compound, which is preferably a basic inorganic salt. Preferably, the enteric coating material is at least about 60% neutralized, more preferably the enteric coating material is at least about 80% neutralized, and most preferably the enteric coating material is at least about 95% neutralized.

The enteric coating optionally contains a plasticizer, such as a citric acid ester, a phthalic acid ester, or any suitable plasticizer.

The method for applying the enteric coating material to the substrate can vary. Substantially any coating method can be used, such as pan coating or fluidized bed coating, with the solution of the enteric coat chosen. As noted previously, preferably this solution is an aqueous solution. The enteric coating materials described previously can be applied to the substrate in an aqueous solution if the pH value of the solution is adjusted to at least 6.5, and more preferably to an alkaline value, most preferably a pH value from about 7 to about 10.

The following specific examples illustrate various aspects of the compositions of the present invention, and are not intended to be limiting in any way. Specific reference is made to Omeprazole for the purposes of description only and without intending to be limiting.

EXAMPLE 1

This example of the composition of the present invention was prepared as follows. The substrate was in the form of an active core, which was prepared by embedding Omeprazole in poloxamer (Pluronic PE 6800), granulating the resulting mass, adding the necessary auxiliary substances to the mass, and compressing the resultant material into tablets. The substrate was then coated with alkaline polyvinyl acetate phthalate as the enteric coating layer.

US 7,255,878 B1

7

8

Ingredients	Quantity per tablet
<u>Substrate</u> (Active Embedded Core)	
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	12 mg
Titanium dioxide	100 mg
Ludipress®	226 mg
Sodium stearyl fumarate	25 mg
<u>Enteric coating layer</u>	
Polyvinyl acetate phthalate	75 mg
Antifoam emulsion	0.25 mg
Sodium hydroxide	12 mg

For the preparation of the substrate, the poloxamer was melted at a temperature of 80° C. Omeprazole, together with 2 mg colloidal silicon dioxide, 8 mg of magnesium carbonate, titanium dioxide and 6 mg of sodium starch glycolate were added and mixed thoroughly. Mixing was continued until the melt solidified. The melt was granulated and the rest of the ingredients added to the granulate. The granulate was then compressed into tablets which contained 20 mg Omeprazole. These tablets, which formed the substrate of the composition, were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared in the following manner. First, the antifoam emulsion was dissolved in water to form an aqueous solution. Polyvinyl acetate phthalate was then stirred into this solution for a final concentration of about 10% weight per volume before sodium hydroxide was added. Sodium hydroxide (1 M solution) was then added to adjust the pH value of the solution to about 8, thereby obtaining a basic solution of the enteric coating material. This solution was then sprayed onto the tablets with an incoming air temperature of 40° C.

EXAMPLE 2

This example of the composition of the present invention was prepared as follows. The substrate was prepared by embedding Omeprazole in poloxamer (Pluronic PE 6800) to form tablets, as for Example 1. However, in this Example, the tablets were then coated with hydroxypropyl methylcellulose acetate succinate (HPMCAS) as the enteric coating layer.

Ingredients	Quantity per tablet
<u>Substrate</u>	
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Sodium starch glycolate	20 mg
Ludipress®	228 mg
Sodium stearyl fumarate	25 mg
<u>Enteric coating layer</u>	
Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS)	43 mg
Triethyl citrate	12 mg
Sodium lauryl sulfate	1.3 mg

-continued

Ingredients	Quantity per tablet
Talc	21.4 mg
Sodium hydroxide	2.3 mg

The tablets were prepared as for Example 1, except that titanium dioxide was omitted. The tablets were then coated in a conventional coating pan with the enteric coating solution, which was prepared as follows. First, triethyl citrate was dissolved in water to form an aqueous solution. Sodium lauryl sulfate was then added to this aqueous solution. The HPMCAS and talc were dispersed in this solution, such that the concentration of HPMCAS was about 10% weight per volume. Sodium hydroxide (1M solution) was then added to adjust the pH value of the solution to a value from about 7 to about 10. The enteric coating was layered over the substrate by spraying the solution with an incoming air temperature of 40° C.

EXAMPLE 3

This example of the composition of the present invention was prepared as for Example 1, except that the enteric coating contained alkaline HPMCP (hydroxypropylmethylcellulose phthalate) rather than HPMCAS.

Ingredients	Quantity per tablet
<u>Substrate</u>	
Omeprazole	20 mg
Poloxamer (Pluronic PE 6800)	200 mg
Colloidal silicon dioxide	7 mg
Sodium starch glycolate	10 mg
Titanium dioxide	83 mg
Ludipress®	145 mg
Sodium stearyl fumarate	25 mg
<u>Enteric coating layer</u>	
HPMC Phthalate (HP-55)	56.2 mg
Triethyl citrate	22.5 mg
Sodium hydroxide	9 mg

The substrate was prepared as described in Example 1, and was then coated in a conventional coating pan with the enteric coating solution by spraying the solution at an incoming air temperature of 40° C. The enteric coating solution was prepared as follows. The HPMC phthalate was suspended in the water to a concentration of about 10% weight per volume (before sodium hydroxide was added). Sodium hydroxide (1M solution) was then added to this aqueous suspension until the HPMCP dissolved. The resultant solution has a pH value in a range of from about 8 to about 10. The triethyl citrate was then added to the resultant solution in order to form the enteric coating solution, which was then layered over the substrate as previously described.

EXAMPLE 4

In this example of the composition of the present invention, the substrate has two parts: a neutral core; and a coating layer containing the active ingredient, which was layered over the neutral core. The substrate was then coated with the enteric coating solution. Hard gelatin capsules were then filled with the resultant pellets.

US 7,255,878 B1

9

<u>Substrate</u>	
Neutral core	Quantity per capsule
Sugar spheres 20/25 (700-850 microns)	161.63 mg

Ingredients	Quantity per capsule
<u>Active coating</u>	
Omeprazole	20.00 mg
Hydroxypropyl methylcellulose 2910	5.33 mg
Hydroxypropyl cellulose	6.00 mg
Lactose	8.00 mg
Disodium phosphate anhydrous	0.64 mg
Sodium lauryl sulfate	0.50 mg
<u>Enteric coating layer</u>	
HPMCAS	21.00 mg
Triethyl citrate	6.00 mg
Sodium lauryl sulfate	0.66 mg
Talc	11.00 mg
Sodium hydroxide	1.12 mg

The composition of the present invention was prepared according to this Example as follows. First, sugar spheres were placed in a fluid bed coating chamber, equipped with a Wurster bottom spraying device. A suspension of the ingredients in water was then prepared so that the concentration was approximately 20% of total solids in water. This active coating suspension was sprayed onto the sugar spheres. A suspension of the enteric coating was prepared according to Example 2. This enteric coating was then sprayed onto the substrate in order to form the finished pellets. The pellets were then placed in capsules.

EXAMPLE 5

This example of the composition of the present invention was prepared with a compressed tablet as the substrate. The tablet was then coated with alkaline HPMCAS (Hydroxypropyl Methylcellulose Acetate Succinate) as the enteric coating layer, preferably having a pH in a range of from about 7 to about 10.

Ingredients	Quantity per tablet
<u>Substrate</u> (Active Compressed Tablet Core)	
Omeprazole	20 mg
Lactose	192.5 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	10 mg
Povidone	10 mg
Sodium stearyl fumarate	7.5 mg
<u>Enteric coating layer</u>	
HPMCAS	16.1 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.04
Sodium hydroxide	0.86 mg

10

For the preparation of the substrate, Omeprazole, together with lactose, magnesium carbonate, sodium starch glycolate, and povidone were mixed thoroughly. The mixture was then granulated with a sufficient quantity of water, and dried. Sodium stearyl fumarate was then added to the mixture, which was then compressed into tablets weighing 250 mg each.

These tablets, which formed the substrate of the composition, were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 6

Stability tests were performed with formulations prepared according to Examples 2 and 3. For the first test, both coated and uncoated tablets prepared according to either Example 2 or Example 3 were placed into a box which was open to the environment. The open box was then stored at 40° C. and 75% relative humidity, which are very stringent conditions. The coated and uncoated tablets were examined initially, after a week and after a month to determine stability. The results are shown in the tables below.

Tablets Prepared According to Example 2

Sampled Material	Appearance of Sample		
	Initial	After One Week	After One Month
coated tablet	off white	deeper off white	deeper off white
uncoated tablet	white	white	white

Tablets Prepared According to Example 3

Sampled Material	Appearance of Sample		
	Initial	After One Week	After One Month
coated tablet	off white	off white	deeper off white
uncoated tablet	white	white	white

The term "deeper off white" refers to a more intense off white color which was observed for some samples, as described in greater detail above. These results show that coated tablets prepared according to either Example 2 or Example 3 showed good stability, even after one month of storage under particularly stringent conditions.

In a second stability test, coated tablets were prepared according to Example 2. These coated tablets were then packed into an Alu/Alu (Aluminum/Aluminum) blister, which is a well known technique in the art for packing certain oral dosage forms. The blister was then stored under accelerated conditions of 30° C. and 60% relative humidity; or 40° C. and 75% relative humidity. Samples of the tablets were examined initially, and after one month of storage under one of these conditions. In addition, samples were assayed to determine the amount of Omeprazole present in the coated tablet, as listed under "Assay" as milligrams of Omeprazole per tablet. A dissolution test was performed, using the accepted USP method. The coated tablets were placed in 0.1 N HCl for 2 hours, followed by a solution at pH 6.8 with stirring with a paddle at 100 rpm for 15 minutes, 30 minutes or 45 minutes. Gastric resistance was also

US 7,255,878 B1

11

examined by placing the coated tablets in a simulated gastric fluid for 2 hours (pH of approximately 1), as is well known in the art. The results are shown in the table below.

	Time (min)	Initial	30° 60% RH	40° 75% RH
Description	NA	Off white	Off white	Off white
Assay	NA	20.4 mg	19.39 mg	19.66 mg
Dissolution	120	0%	0%	0%
	135	52%	42%	39%
	150	96%	85%	90%
	165	105%	99%	104%
Gastric Resistance	NA	101%	98%	96%

These results show that the coated tablets, prepared according to Example 2, show good stability and gastric resistance, yet are also able to dissolve in an appropriate time-dependent manner.

EXAMPLE 7

A one-way pharmacokinetic pilot study was performed in vivo for testing the pharmacokinetic profile of the coated tablets, which were prepared according to Example 2. The study was performed with ten healthy male volunteers, who received a single dosage of the coated tablets, containing 20 mg of Omeprazole. The results showed that Omeprazole administered in the coated tablets of the present invention had a similar lag time to absorption in comparison to a previous study performed with the reference product, which is the 20 mg Omeprazole dosage form of the formulation of Astra (Aktiebolaget Hassle), and also as described in the literature (see for example Duvauchelle, T. et al., "Comparative Bioavailability Study of Two Oral Omeprazole Formulations After Single and Repeated Administrations in Healthy Volunteers", *Pharmacokinetics*, 16: 141-149, 1998). The lag time to absorption is defined as the time between the administration of the formulation and the first detection of the active ingredient in the samples taken from the subject, according to the sampling method employed.

In addition, comparable bioavailability was achieved with the coated tablets of the present invention, both to values obtained in the previous study with the reference product and to values which were described in the literature (see for example the previously referenced article in *Pharmacokinetics*). Furthermore, the values obtained for C_{max} and T_{max} concerning the rate of absorption were comparable to results obtained in the previous study performed with the reference product, and as described in the literature (see for example the previously referenced article in *Pharmacokinetics*). Thus, the coated tablets of the present invention clearly show good performance both in vitro, as described in Example 6, and in vivo.

EXAMPLE 8

Coated pellets were prepared according to the process previously described above in Example 4. However, the pellets were coated with the following suspension:

Enteric coating (quantities per capsule)	
HPMCAS	21.00 mg
Triethyl Citrate	6.00 mg

12

-continued

Enteric coating (quantities per capsule)	
Sodium lauryl sulfate	0.66 mg
Colloidal silicon dioxide	2.10 mg
Sodium hydroxide	1.12 mg

EXAMPLE 9

Although the previous Examples used aqueous solutions for providing an optimal coating, the possibility of increasing the concentration of the enteric coating polymer by using an alcohol-based solution was studied in this Example.

Coated pellets were prepared according to the process of Example 4, except that these pellets were coated with the following solution, to obtain the required protection in an acidic environment.

Enteric coating		
Solution prepared		Quantities per capsule
Alcohol 95%	1.900 kg	N/A
Water	0.830 kg	N/A
HPMCAS	0.476 kg	21.00 mg
Triethyl citrate	0.136 kg	6.00 mg
Sodium lauryl sulfate	0.015 kg	0.66 mg
Colloidal silicon dioxide	0.047 kg	2.1 mg
Sodium hydroxide	0.025 kg	1.12 mg

EXAMPLE 10

Substrate (Active Compressed Tablet Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Magnesium carbonate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

Enteric coating layer	
Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™ (pink pigment)	10.8 mg

For the preparation of the substrate, Omeprazole was mixed together thoroughly with lactose, sodium starch glycolate, magnesium carbonate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4, with the addition of a pigment to the enteric coating material.

US 7,255,878 B1

13
EXAMPLE 11

Stability tests were performed with the formulation prepared according to Example 10. For the tests, the tablets were packed into alu-alu blister. The blister was then stored under room temperature or under accelerated conditions of 30° C. and 60% relative humidity (RH), or 40° C. and 75% relative humidity. Samples of the tablets were examined initially and after 6 months of storage under one of these conditions. In addition samples were assayed. A dissolution test was performed, and gastric resistance was also examined. The tablet gave good stability results even after storage at 40° C. The results are shown in the table below.

Test performed	Initial	25° C. 6 month	30° C./60% RH 6 month	40° C./75% RH 6 month
Visual Description	conform	conform	conform	conform
Assay	19.76 mg per tablet	20.19 mg per tablet	19.97 mg per tablet	19.28 mg per tablet
Dissolution	96%	96%	96%	96%
Gastric Resistance	96%	96%	95%	94%

EXAMPLE 12

A two-way pharmacokinetic study was performed in vivo for testing the bioequivalence of the coated tablets which were prepared according to Example 10, as compared to the reference product which is the 20 mg Omeprazole dosage form of the formulation of Astra (Sweden), called Losec™. The study was performed on 39 volunteers. As shown in the table below, the results of the study showed that the two products exhibited very similar pharmacokinetic profiles, such that the two formulations can be considered to be bioequivalent.

Formulation	AUC (ng × hour/ml)	Cmax (ng/ml)	Tmax (hours)
Formulation of the present invention (Example 10)	426 ± 256	217 ± 109	1.08 ± 0.64
Losec™ (Astra)	434 ± 226	246 ± 113	1.56 ± 0.79

EXAMPLE 13

Substrate (Active Compressed Tablet Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Sodium hydrogen carbonate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

14

Enteric coating layer	
Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™	10.8 mg

For the preparation of the substrate, Omeprazole was thoroughly mixed together with lactose, sodium starch glycolate, sodium hydrogen carbonate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 14

Substrate (Active Compressed Tablet Core)	
Ingredients	Quantity per tablet
Omeprazole	20 mg
Lactose	203 mg
Trisodium citrate	10 mg
Sodium starch glycolate	10 mg
Sodium stearyl fumarate	7 mg

Enteric coating layer	
Ingredients	Quantity per tablet
HPMCAS	16 mg
Triethyl citrate	4.5 mg
Sodium lauryl sulfate	0.5 mg
Talc	8.14 mg
Sodium hydroxide	0.86 mg
Sepisperse™	10.8 mg

For the preparation of the substrate, Omeprazole was mixed thoroughly together with lactose, sodium starch glycolate, trisodium citrate and sodium stearyl fumarate. The mixture was then compressed into tablets weighing 250 mg each. These tablets were then transferred into a conventional coating pan and coated with the enteric coating layer, prepared as described in Example 4.

EXAMPLE 15

Stability tests were performed with the formulations prepared according to Examples 10, 13 and 14. Both coated and non-coated tablets were placed into an open box and stored at 40° C. and 75% relative humidity, which are very stringent conditions. The coated and uncoated tablets were examined initially after 1 week and again after 2 weeks to determine stability. The results are shown in the tables below.

US 7,255,878 B1

15

Tablets prepared according to Example 10			
Sampled material	Appearance of sample		
	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

Tablets prepared according to Example 13			
Sampled material	Appearance of sample		
	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

Tablets prepared according to Example 14			
Sampled material	Appearance of sample		
	Initial	After 1 week	After 2 weeks
Coated	Pink	Pink	Pink
Uncoated	White	White	White

While the invention has been described with respect to a limited number of embodiments, it will be appreciated that many variations, modifications and other applications of the invention may be made.

What is claimed is:

1. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of:

forming a substrate with the benzimidazole derivative; preparing a solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate; neutralizing said solution by addition of an alkalinizing material comprising a material selected from the group consisting of an inorganic or organic alkaline compound; and applying a single layer of said neutralized solution directly to said substrate, without an intermediate layer between said substrate and said enteric coating.

2. The method of claim 1, wherein said neutralized solution is at least about 60% neutralized.

3. The method of claim 2, wherein said neutralized solution is at least about 80% neutralized.

4. The method of claim 3, wherein said neutralized solution is at least about 95% neutralized.

5. The method of claim 1, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

6. The method of claim 1, wherein said substrate is formed by direct compression.

7. The method of claim 1, wherein said substrate is formed by wet granulation.

8. The method of claim 1, wherein said substrate is formed by coating on an inert core.

16

9. The method of claim 1, wherein said coating comprises spraying.

10. The method of claim 1, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40° C.

11. The method of claim 1, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.

12. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of:

forming a substrate with the benzimidazole derivative; preparing an aqueous solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate;

neutralizing said solution by addition of an alkalinizing material comprising a material selected from the group consisting of sodium, potassium or ammonium hydroxide;

spraying a single layer of said neutralized solution directly over said substrate, without an intermediate layer between said substrate and said enteric coating.

13. The method of claim 12, wherein said neutralized solution is at least about 60% neutralized.

14. The method of claim 13, wherein said neutralized solution is at least about 80% neutralized.

15. The method of claim 14, wherein said neutralized solution is at least about 95% neutralized.

16. The method of claim 12, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

17. The method of claim 12, wherein said substrate is formed by direct compression.

18. The method of claim 12, wherein said substrate is formed by wet granulation.

19. The method of claim 12, wherein said substrate is formed by coating on an inert core.

20. The method of claim 12, wherein said coating comprises spraying.

21. The method of claim 12, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40° C.

22. The method of claim 12, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.

23. A method for producing a stable tablet composition for a benzimidazole derivative, the method consisting essentially of:

forming a substrate with the benzimidazole derivative; preparing an aqueous solution of an enteric polymer selected from the group consisting of HPMCAS, CAP, polyvinyl acetate phthalate, cellulose acetate trimellitate, polymethacrylic acid methacrylate, and ethyl methacrylate;

neutralizing said solution by addition of an alkalinizing material comprising at least ammonium hydroxide; adding a plasticizer to said solution before or after said neutralizing; and

directly coating said substrate with a single layer of said neutralized solution, without an intermediate layer between said substrate and said enteric coating.

24. The method of claim 23, wherein said neutralized solution is at least about 60% neutralized.

25. The method of claim 23, wherein said neutralized solution is at least about 80% neutralized.

US 7,255,878 B1

17

26. The method of claim 25, wherein said neutralized solution is at least about 95% neutralized.

27. The method of claim 23, wherein said substrate is formed by melting poloxamer and by mixing the benzimidazole derivative into said poloxamer.

28. The method of claim 23, wherein said substrate is formed by direct compression.

29. The method of claim 23, wherein said substrate is formed by wet granulation.

30. The method of claim 23, wherein said substrate is 10
formed by coating on an inert core.

18

31. The method of claim 23, wherein said coating comprises spraying.

32. The method of claim 23, wherein said applying said neutralized solution comprises spraying said solution with an incoming air temperature of at least 40° C.

33. The method of claim 23, wherein said applying said neutralized solution comprises a method selected from the group consisting of pan coating and fluidized bed coating.

* * * * *